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ABSTRACT 
Background. A high plasma level of total homocysteine (tHcy) is a risk factor for 
cardiovascular disease, and is related to important components of atherosclerosis such as 
inflammation and endothelial dysfunction. 
Objectives. To test the effect of homocysteine-lowering B-vitamin therapy on 1) tHcy, and 
metabolites and determinants of tHcy, 2) inflammatory markers associated with 
atherosclerosis and 3) coronary endothelial and vascular function. 
Design. Single centre, double-blind clinical interventional study, randomised in a 2x2 
factorial design into daily oral treatment with A) folic acid (0.8 mg)/vitamin B12 (0.4 
mg)/vitamin B6 (40 mg), B) folic acid/vitamin B12, C) vitamin B6 alone or D) placebo. For 
the first two weeks, groups A and B received additional folic acid 5 mg/day. 
Subjects and methods. Two sub-groups of patients participating in the Western Norway B-
vitamin Intervention Trial (WENBIT); Patient group 1: Ninety patients (21 female, aged 38-
80 years) with suspected coronary artery disease (CAD). Blood samples were collected at 
baseline, after 3 days, 2 weeks, 1, 3, 6 months and one year of B-vitamin intervention. An oral 
methionine loading test (0.1 g/kg body weight) was done at baseline and after 3 months. 
Patient group 2: Forty patients (8 female, aged 39-74 years) with CAD. They were examined 
at baseline, and after 9 and 24 months, coronary blood flow (CBF) was assessed by coronary 
angiography and Doppler flow-wire measurements during intra-coronary infusion of saline 
(basal), incremental (0.72 µg/min, 7.2 µg/min and 36.0 µg/min) doses of acetylcholine, 2.4 
mg/min adenosine and nitroglycerin. 
Results. In patient group 1, we documented a reduction of 31% on plasma tHcy and a 
pronounced reduction of post methionine load (PML) tHcy by folic acid/vitamin B12. 
Vitamin B6 reduced cystathionine and particularly PML cystathionine. There was a strong 
inverse relation between PML betaine and PML increase in tHcy, a relation that was 
abolished by folic acid/vitamin B12 treatment for 3 months. Treatment with folic acid/vitamin 
B12 or vitamin B6 for 6 months had no effects on levels of neopterin, sCD40L, IL 6 or CRP. 
During the two years of follow-up of patient group 2, basal CBF and adenosine-stimulated 
CBF increased among patients treated with folic acid /B12 as opposed to those not receiving 
folic acid /B12. 
Conclusions. The doses of folic acid/B12 applied in WENBIT give adequate tHcy lowering 
effect. Cystathionine may be a useful marker for assessment of the vitamin B6 effect. Plasma 
betaine is a strong determinant of the PML increase in tHcy in patients not supplemented with 
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B-vitamins which emphasizes the complementary relationship between betaine and folate 
metabolism. Although we observed improved coronary vascular function after treatment with 
folic acid/vitamin B12, failure to reverse inflammatory processes associated with 
atherosclerosis may partly explain the negative results of previous B-vitamin intervention 
trials among patients with established CVD. 
INTRODUCTION 
Cardiovascular disease 
Cardiovascular disease (CVD) is a major cause of morbidity and mortality in Norway 
(Figure1) and most other countries, although age-adjusted mortality rates have been declining 
in the last 30 years. Epidemiologic studies have demonstrated important modifiable risk 
factors for ischemic heart disease, such as smoking, diabetes, hypertension, dyslipidemia and 
obesity. It has been suggested that these conventional risk factors only explain about half of 
the variance in coronary heart disease, but the role of these risk factors is probably 
underestimated 1. A meta-analyses of studies on coronary heart disease (CHD) shows that 
more than 80 % of patients have at least one of these conventional risk factors 2. It is, 
however, difficult to predict the risk for CHD on individual basis, even with sophisticated 
algorithms 3. In order to improve risk assessment and more accurately distinguish between 
moderate and high risk of CHD, research has focused on new risk markers associated with 
CVD. 
The subject of this thesis is homocysteine metabolism and its relation to CHD. 
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Homocysteine 
History 
A new sulphur amino acid was discovered in 1932 and called homocysteine 4 (Figure 2). One 
year later, a case report of a retarded boy with dislocated ocular lenses and skeletal 
abnormalities, who died of a massive cerebral infarction with arteriosclerosis and thrombosis 
of the carotid artery, was published 5. Later, excretion of homocystine in urine, 
homocystinuria, was described in children with mental retardation, growth disturbances and 
thrombosis of arteries and veins 6,7. A metabolic defect in the homocysteine metabolism 
affecting the vitamin B6-dependent enzyme, cystathionine ß-synthase (CBS), was discovered 
in these children 8. New cases lead to the discovery of other enzymatic defects of the 
homocysteine metabolism; deficiency of the vitamin B12-dependent enzyme methionine 
synthase (MS) 9 and deficiency of methylenetetrahydrofolate reductase (MTHFR) 10. 
 
 
Figure 2. Structure and distribution of different homocysteine forms in plasma. From 11, adapted from 
Ueland 12. 
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Homocysteine and atherosclerosis, background 
In 1949 atherosclerotic lesions was described in vitamin B6 deficient monkeys 13 and later in 
choline deficient rats 14. With the presentation of patients suffering from inborn enzyme 
defects leading to homocystinuria and premature atherothrombotic disease, the link between 
homocysteine and B-vitamin status and CVD was established 15. Without treatment, about 50 
% of these patients with homocystinuria suffered from a thromboembolic event and 20 % died 
before the age of 30 years 16. In 1976, a study of Wilcken and Wilcken showed significantly 
higher homocysteine levels among patients with coronary artery disease before the age of 50 
years compared to a control group 17. 
Early meta-analysis of retrospective observational studies on the effect of moderate 
elevated total homocysteine concentration (tHcy), found tHcy as a graded independent risk 
factor of CHD and estimated a relative risk of 1.7 associated with a 5 µmol/L increment in 
tHcy level 18. Later, meta-analysis of prospective observational studies reported that after 
adjustments for conventional risk factors, a 25 % lower plasma tHcy concentration was 
associated with only 11 % lower risk of CHD 19. 
The association between tHcy and CHD in prospective studies is supported by 
observations from investigations using Mendelian randomisation. These studies are based on 
the occurrence of 25 % higher tHcy level among subjects with a homozygous (TT) mutation 
in the MTHFR gene compared with the common (CC) variant. Analysing 80 studies with 
26000 cases, those who were homozygous TT had an overall 14 % higher risk of CHD and a 
2.2 µmol/L higher level of tHcy compared to those who had the CC genotype, although with 
some heterogeneity between geographically regions 20. All together, cohort and MTHFR 
677C → T polymorphism studies show a significant association between tHcy level and risk 
of CHD 21, and warrant mechanistic and clinical intervention studies to explore the effects of 
homocysteine-lowering therapy. 
 
Biochemistry and measurements 
Homocysteine is a sulphur amino acid, generated through demethylation of the essential 
amino acid methionine. The concentration in plasma of its free reduced form is, under normal 
conditions, very low, only 1-2 % of tHcy. Most of homocysteine in plasma is oxidized and 
bound to albumin or exists as a disulfide (homocystine or homocysteine-cysteine) (Figure 2). 
The sum of all these homocysteine forms is denoted tHcy 11. 
Methods for measuring tHcy were introduced more than 20 years ago. All assays are 
based on treating plasma or serum with a reducing agent to convert all homocysteine forms to 
its reduced thiol, which is then measured directly or after derivatization 11. 
 
Methionine loading test 
To increase the sensitivity of diagnosing hyperhomocysteinemia, a methionine loading test 
has been used. After overnight fasting, oral methionine (0.1 g/kg body weight) is administered 
and post methionine load (PML) blood samples are drawn 4 (6) hours after methionine intake 
22,23. Plasma PML samples in patients with CHD show a 30-times increase of methionine, thus 
stressing the metabolic pathways resulting in a 3-times increase of tHcy and 9-times increase 
of cystathionine 24. Originally, this was done to detect heterozygosity for CBS deficiency, but 
also subjects without CBS mutations and with normal fasting tHcy demonstrate elevated PML 
tHcy 25, suggesting that additional information is obtained with the test. In contrast, a light 
meal will not significantly influence tHcy level, whereas a heavy protein rich meal may 
increase tHcy by 10 – 15 % 26. 
 
 
Figure 3. Betaine metabolism, 
homocysteine remethylation, and 
transsulfuration. 
Ado indicates adenosine; AdoHcy, S-
adenosylhomocysteine; AdoMet, S-
adenosylmethionine; BAD, betaine 
aldehyde dehydrogenase; Bet, 
betaine; BHMT, betaine-homocysteine 
methyltransferase; CBS, cystathionine 
ß-synthase; CL, cystathionine γ-lyase; 
CH3THF, methyltetrahydrofolate; CO, 
choline oxidase; DMG, 
dimethylglycine; Cys, cysteine; Cysta, 
cystathionine; Hcy, homocysteine; 
MAT, methionine adenosyltransferase; 
Met, methionine; MT, 
methyltransferase; MTR, methionine 
synthase; SAHH, S-
adenosylhomocysteine hydrolase; 
THF, tetrahydrofolate. 
Adapted from paper 2 
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Metabolism 
Homocysteine content in foods are very small 27.Almost all Hcy is formed as a metabolic 
product of the essential amino acid methionine, which donate a methyl group, and through 
several enzymatic steps is converted to homocysteine. The metabolism of homocysteine and 
its relation to B-vitamins are summarised in Figure 3. 
The concentration of tHcy is dependent on the balance between formation, as 
described above, and salvage through remethylation to methionine or degraded through 
transsulfuration. 
Remethylation to methionine is in most tissues catalysed by the folate-dependent 
enzyme methionine synthase (MS) with vitamin B12 as cofactor and 5-methyltetrahydrofolate 
(5-MTHF) as methyl donor. Alternatively, in liver and kidney homocysteine is remethylated 
to methionine by betaine-homocysteine methyltransferase (BHMT) with betaine as a methyl 
donor. 
Degradation through transsulfuration is catalyzed first by cystathionine ß-synthase 
(CBS) to cystathionine, and then by cystathionine γ-lyase (CL) to cysteine; both enzymes 
dependent on vitamin B6 as cofactor. 
 
Determinants of homocysteine level 
Genetic disorders inactivating key enzymes (CBS 8, MS 28 or MTHFR 29) of homocysteine 
metabolism may cause serve hyperhomocysteinemia. Other genetic variants, such as MTHFR 
677C → T polymorphism, may cause a mild to moderate elevation of tHcy 30, especially in 
subjects with impaired folate status 31. Other factors associated with tHcy level include age, 
gender, kidney function, folate deficiency, vitamin B12 deficiency, smoking, coffee intake, 
physical activity, blood pressure, and malignant diseases 32. 
 
Mechanisms relating homocysteine to cardiovascular disease 
Numerous studies demonstrate that hyperhomocysteinemia is related to an increased risk of 
the existence, extent, progression and prognosis of CVD 33,34. The mechanisms of this 
association are not fully understood 33,35. Recent data indicate that homocysteine is associated 
with several important components of atherogenesis, including endothelial function, platelet- 
and immune activation and inflammation 36-38. 
Intact endothelium is important for the maintenance of vascular integrity and regulates 
vasomotor tone through release of nitric oxide to meet increased blood flow demands during 
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physical strain. Endothelial dysfunction is an early marker of atherosclerotic disease, it is 
involved in the pathogenesis, and predicts future cardiac events 39,40. Various treatment 
strategies have been shown to improve endothelial function and cardiovascular prognosis, 
including statins, angiotensin converting enzyme inhibitors and exercise 39. High doses of 
folic acid given to patients with CVD improve endothelial function measured as flow-
mediated dilatation (FMD) in forearm arteries in some, but not in all studies 41. However, low 
dose (0.4 mg/d) folate therapy seems to be ineffective 42,43. Typically, the duration of the 
studies was for a few weeks to months 41. 
Inflammation and persistent immune activation are hallmarks of the atherosclerotic 
process 44. The markers, C-reactive protein (CRP), CD40 ligand (CD40L) and neopterin, 
represent different inflammatory pathways related to atherogenesis. CRP is an acute phase 
reactant; the production of CRP is stimulated by interleukin (IL)-6 effects on the liver. CRP 
represents an overall marker of the inflammation and is extensively investigated and 
characterized 45. CD40L is produced by many cell types, but is excreted mainly from platelets 
and is related to unstable coronary artery disease 46. Soluble CD40L (sCD40L) may therefore 
reflect the role of activated platelets in inflammation 47. Neopterin is a pteridine which 
increases during activation of the cellular part of inflammation, and is released from activated 
monocytes through stimulation by interferon gamma (IFN-γ) from T-lymphocytes 48. 
Neopterin has been related to the extent 49, complexity 50 and progression 51 of the 
atherosclerotic disease. Furthermore, neopterin is strongly related to the homocysteine 
homeostasis 52. 
The thiol group of homocysteine may undergo auto-oxidation in plasma to generate 
reactive oxygen species (ROS), and thereby induce (endothelial) cell injury through a 
mechanism involving oxidative stress 53. The results are conflicting, and one study 
demonstrates that homocysteine does not significantly increase the production of ROS and 
may, as opposed to pro-oxidant characteristics, display antioxidant effects 54. 
In two recent reports, homocysteine was shown to reduce the concentration of HDL-
cholesterol in plasma by inhibiting the hepatic synthesis of apoA-I, the main HDL 
apolipoprotein 55,56. Since a low concentration of HDL-cholesterol predicts development 
cardiovascular disease 57, this mechanism possibly links homocysteine level to the 
development of atherosclerosis. 
In patients with homocystinuria, tissue samples showed marked neointima 
proliferation 15. It has been reported that elevated homocysteine levels stimulate proliferation 
of vascular smooth muscle cells 58 and increase collagen deposition in vessel walls 59. These 
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effects of homocysteine are of potential importance, not only for promoting atherosclerosis, 
but also in relation to restenosis after coronary artery intervention 60,61. 
 
Treatment of elevated homocysteine levels 
The idea of treating elevated homocysteine was pioneered in patients with homocystinuria 
due to cystathionine synthase deficiency. Treatment of homocystinuria with pyridoxine 
decreased the plasma tHcy concentration and urinary excretion of methionine and 
homocystine 62, and adding betaine treatment substantially decreased plasma tHcy levels in 
pyridoxine non-responders 63. Later, when epidemiological studies showed association 
between moderate hyperhomocysteinemia and CVD, B-vitamin treatment to lower tHcy was 
introduced with the aim of reducing risk of CVD and its complications 64. A meta-analysis of 
randomised trials demonstrated a 23 % tHcy-lowering effect of a daily folic acid dose of 0.8 
mg with an additional 7 % reduction of tHcy by adding cyanocobalamin 0.4 mg, and no 
further reduction by adding vitamin B6 65. 
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AIMS OF THE STUDIES 
The aims of these studies were to investigate effects of homocysteine-lowering B-vitamin 
therapy, as administered in the Western Norway B-vitamin Intervention Trial (WENBIT), on 
patients with established coronary artery disease. The specific objects of this work were: 
 
1. To evaluate acute and long-term effects of the B-vitamin intervention on tHcy and related 
metabolites, in the basal state and after repeated methionine loading. 
2. To investigate the association between plasma betaine and tHcy before and after 
methionine loading and the effect of long-term B-vitamin treatment on these associations. 
3. To investigate the effects of tHcy-lowering B-vitamins on inflammatory markers 
associated with atherosclerosis. 
4. To evaluate the long-term effect of tHcy-lowering B-vitamin therapy on coronary vascular 
function. 
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SUMMARY OF RESULTS 
Paper 1. Changes in basal and postmethionine load concentrations 
of total homocysteine and cystathionine after B vitamin 
intervention. 
Am J Clin Nutr 2004;80(3):641-8. 
This study (WENBIT 90 sub-study) is based on the first 90 patients recruited to the WENBIT 
study at Haukeland University Hospital in the period April 1999 to September 1999. The 
WENBIT 90 sub-study was designed to investigate in details the biochemical associations and 
responses of B-vitamin therapy. Patients, aged 38 – 80 years (21 women and 69 men), were 
randomised to daily oral treatment with A) folic acid (0.8 mg)/vitamin B12 (0.4 mg)/vitamin 
B6 (40 mg), B) folic acid/B12, C) B6 alone or D) placebo. For the first two weeks, groups A 
and B received additional folic acid 5 mg/day. Blood sampling was done at baseline, after 3 
days, 2 weeks, 1, 3, 6 months and later at 12 months of B-vitamin intervention. An oral 
methionine loading test (0.1 g/kg body weight) was done at baseline and after 3 months. Post-
methionine load blood samples were drawn 4 hours after methionine intake. 
We found that mean plasma folate concentration significantly increased from 8.1 
nmol/L to a steady state of 57.0 nmol/L in subjects randomised to treatment with folic acid 
0.8 mg/day (with additional folic acid 5 mg/day for the first two weeks). Interestingly, plasma 
cobalamin was significantly increased already at day three in the groups treated with oral 
vitamin B12 0.4 mg/day (from 374 pmol/L to 448pmol/L), and a moderate additional increase 
was observed during the next six months (to 546 pmol/L). Following treatment with vitamin 
B6 40 mg/day, concentrations of PLP was increased 10-fold within three days, and PLP 
remained at this level during the observation period. 
The main results of this study were documentation of an immediate tHcy decrease 
following supplementation with folic acid/vitamin B12. A significant reduction was observed 
at three days and a maximum reduction of 31% within two weeks. Also, the effect was 
maintained for at least six months despite the lower long-term dose. Vitamin B6 had no effect 
on tHcy, but reduced cystathionine by 31 %. PML tHcy increased almost 3-times and PML 
cystathionine 9-times. After 3 months of treatment, PML tHcy was significantly reduced both 
by folic acid/vitamin B12 (22 %) and vitamin B6 (10 %), with the greatest reduction achieved 
by the combination of these vitamins (27 %). Vitamin B6 treatment for three months reduced 
PML cystathionine by 42% compared to baseline, and almost completely suppressed high 
PML cystathionine concentrations. 
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Paper 2. Betaine as a determinant of postmethionine load total 
plasma homocysteine before and after B-vitamin supplementation. 
Arterioscler Thromb Vasc Biol 2004;24(2):301-7. 
Based on the patients in the WENBIT-90 sub-study, we studied betaine and its relation to 
homocysteine metabolism. This was done after methionine loading, a situation that maximally 
challenges the methionine-homocysteine pathways. 
We found that plasma betaine level increased transiently after methionine loading and 
is remarkably stable over time. Our study confirmed other reports showing higher betaine 
levels for men compared with women. The main finding was a strong inverse association 
between PML betaine and PML increase in tHcy, an association that was essentially abolished 
in patients receiving folic acid/vitamin B12. 
 
Paper 3. Homocysteine-lowering therapy does not affect 
inflammatory markers of atherosclerosis in patients with stable 
coronary artery disease. 
J Intern Med 2007; 262:244-253. 
This study is also based on the WENBIT-90 sub-study. The current investigation was 
designed to assess the effects of homocysteine-lowering B-vitamins on inflammatory markers 
associated with atherosclerosis. We measured the biomarkers C-reactive protein (CRP) (and 
interleukin (IL)-6 which stimulates the production of CRP), CD40L and neopterin, since these 
markers represent three different lines in the inflammation cascade related to atherogenesis. 
CRP represents an overall marker of the inflammatory cascade and is extensively investigated 
and characterised. CD40L is produced by many cell types, but is excreted mainly from 
platelets and is related to unstable coronary artery disease. Soluble CD40L (sCD40L) may 
therefore reflect the role of activated platelets in inflammation. Neopterin is a pteridine, which 
reflects activation of the cellular part of inflammation, and is released from activated 
monocytes through stimulation by interferon gamma from T-lymphocytes. Neopterin is 
related to the extent, complexity and progression of the atherosclerotic disease. Furthermore, 
neopterin is strongly related to the homocysteine homeostasis. 
Both tHcy and neopterin were significantly associated with creatinine, age and gender. 
After adjustment for GFR, tHcy was still significantly correlated with neopterin (r=0.38, 
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p<0.001). Despite the fact that plasma tHcy was lowered 33% by folate 0.8 mg/vitamin B12 
0.4 mg, and that a high dose of vitamin B6 (40 mg) was given, no significant changes in the 
neopterin, sCD40L, IL-6 or CRP were observed. 
 
Paper 4. Folic acid intervention increases coronary blood flow in 
patients with stable coronary artery disease. 
Submitted. 
The objective of this substudy of WENBIT, was to evaluate the long-term effect of 
homocysteine-lowering B-vitamin therapy on coronary vascular function. The study 
population was 40 patients with established stable CAD receiving conventional medical 
therapy, including statins, and with no selection according to tHcy levels at baseline. 
After successful treatment of at least one significant coronary stenosis, a non-
intervened coronary artery was used for coronary function testing (study vessel). Patients 
were followed with repeated testing after nine months, and 35 patients returned for a third 
testing after two years of vitamin treatment. 
Our study demonstrated that two years of treatment with moderate doses of folic acid 
and vitamin B12 improved basal coronary blood flow and blood flow at maximum 
hyperaemia induced by adenosine, reflecting improved coronary vascular function. In 
contrast, folic acid/vitamin B12 did not improve coronary endothelial function as measured 
by flow-induced change in coronary vessel diameter or change in flow following stimulation 
with acetylcholine. Vitamin B6 treatment did not change any of the vascular function 
variables. 
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DISCUSSION 
General introduction 
Although epidemiologic and clinical data indicate that hyperhomocysteinemia is associated 
with CVD 33,34,36-38, exact mechanisms relating homocysteine with atherosclerosis 
development have not been determined 21,33,66. Notably, some data suggest that important 
determinants of the tHcy level, such as folate and vitamin B6, may be associated with CVD 
and vascular function independently of the tHcy level 67-70. These B-vitamins influence other 
metabolic pathways in addition to homocysteine, vitamin B6 alone acts as a co-factor of more 
than hundred different reactions 71. Based on these observations, several randomised clinical 
trials with homocysteine-lowering B-vitamins have been initiated in order to investigate 
whether homocysteine is causally related to atherosclerosis 72. 
WENBIT is a prospective, randomised double-blind placebo controlled secondary 
prevention study on the clinical effects of B-vitamin treatment in adults having undergone 
coronary angiography for suspected CAD or aortic valve stenosis. The studies presented in 
this thesis, are sub-studies of WENBIT, designed to assess effects of homocysteine-lowering 
therapy from a mechanistic point of view. 
 
Materials and methods 
Population 
All patients had to be eligible in WENBIT; men and women aged >18 years undergoing 
coronary angiography for suspected CAD and/or aortic valve stenosis at Haukeland 
University Hospital were included. Exclusion criteria were inability to follow-up, 
participation in other trials, known alcohol abuse, serious mental illness or cancer. Patient 
data were collected from patient-administered questionnaires, and a full routine medical 
examination was done at baseline before starting vitamin therapy. 
The current thesis present data based on two sub-groups of patients from WENBIT: 
WENBIT 90. The group, WENBIT 90, is confined to the first 90 consecutive patients 
who were recruited at start of the WENBIT study, in the period of April 1999 to September 
1999. Patients underwent frequent follow-up during the initial 6 months of the intervention, 
and the study was designed to investigate mechanisms and biochemical effects of provided 
treatment. 
Follow-up was not complete. One patient died, 2 patients withdrew their consent. A 
total of 81 patients (90%) attended at the second methionine loading at three months, 83 
(92%) patients attended the visit at 6 months and 74 patients (82%) attended all six visits. 
Patients were all Caucasian, 21 female and 69 male, with median age 62 (range 38-80) 
years. Major characteristics of the patients are given in Table 1. Coronary angiography was 
performed three days after inclusion. 
Non-fasting (basal) blood samples were collected at baseline, after 3 days, 2 weeks, 1, 
3 and 6 months of B-vitamin intervention. Times since last meal and last big meal were noted. 
An oral methionine loading test (0.1 g/kg body weight) was done at baseline and after 3 
months. Post-methionine load blood samples were drawn 4 hours after methionine intake 
 
 
 
 
Invasive sub-study of vascular function. Patients with stable CAD scheduled for 
elective percutaneous coronary intervention were eligible. Additional exclusion criteria were 
predicted high risk for procedural complications, severe chronic obstructive pulmonary 
disease, pulmonary hypertension, significant valvular disease, glaucoma, poorly regulated 
diabetes, or use of systemic corticosteroids. There should be no indication for starting 
vasoactive medical therapy at the time of inclusion. All patients were treated with statins for 
at least two months prior to inclusion. 
A total of 40 patients (8 female and 32 male) with median age 57 (range 39-74) years 
were enrolled. Key baseline demographic and clinical characteristics and medical treatment 
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are given in Table 2. Mean (SD) serum folate was 12.2 (6.5) nmol/L, cobalamin 381 (129) 
pmol/L, plasma pyridoxal phosphate (PLP) 43.3 (25.0) nmol/L and tHcy 10.7 (2.9) µmol/L. 
 
 
 
 
Intervention 
Using a 2x2 factorial block design, patients were randomised into 4 groups of daily oral 
treatment with A) folic acid (0.8 mg)/vitamin B12 (0.4 mg)/vitamin B6 (40 mg), B) folic 
acid/B12, C) B6 alone or D) placebo. This design, allow us to discriminate the effects of folic 
acid/vitamin B12 and vitamin B6. For the first two weeks, groups A and B received additional 
folic acid 5 mg/day to secure rapid initial effect. Packages of trial capsules were prepared and 
given serial number in random order in blocks of 20 by Alpharma A/S (Copenhagen, 
Denmark). 
 
Procedures and measurements 
Blood collection, storage and analyses. Blood sampling was done by study personal to 
ensure adequate handling. The concentration of homocysteine increases within hours when 
stored in room temperature or if samples are not separated from blood cells 11. Our 
measurements of tHcy and metabolites were done in EDTA-plasma, samples were placed on 
ice, centrifuged within 30 min and stored at -80 ºC until further analysed. Analyses of 
vitamins, tHcy and related metabolites were done at the laboratories of Locus for 
Homocysteine and Related Vitamins. Routine blood analyses, including haematological 
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parameters, renal function markers and lipid related factors, were analysed at the Central 
laboratory of the Haukeland University Hospital. Inflammatory parameters were measured 
with commercially available immunoassays 73. 
 
 
Figure 4. Schematic illustration 
of coronary flow measurements. 
A guiding catheter is introduced to 
the left main ostium. An infusion 
catheter with a doppler wire inside is 
placed in the coronary artery to be 
studied. Flow measurements are 
done during infusion, diameter 
measurements is done by 
quantitative angiography (QCA) 
distal and proximal to the tip of the 
infusion catheter. 
 
 
Assessment of coronary vascular function. Measurements were done during consecutive 
intracoronary administration of saline, acetylcholine, adenosine and nitroglycerin. A Doppler 
guide wire was placed in a non-branching segment of the study vessel through the inner 
lumen of a 2.9-French coronary infusion catheter (UltraFuse-X ) ending 1 cm distal to the 
catheter tip (Figure 4). 
Infusions through the UltraFuse-X catheter were done as follows in seven steps: 1) 
Saline 0.9% for three minutes, 2-4) incremental dosage (0.72 µg/min, 7.2 µg/min and 36.0 
µg/min) of acetylcholine for three minutes and 20 seconds each (estimated transit time of 20 
seconds), 5) saline 0.9% for approximately five minutes until return to basal flow, 6) 
adenosine at a dose rate of 2.4 mg/min for 3 min and 20 sec., and finally the infusion line was 
flushed with saline, and 7) a 0.2 mg bolus of nitroglycerin was given. Average peak flow 
velocity (APV) was continuously recorded (Figure 5). At the end of each infusion step, an 
angiogram was done in the same position and angle. A coronary artery segment of 10 mm, 2-
3 mm distal to the Doppler wire, was used for mean diameter measurement by digitalized 
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quantitative coronary angiography (QCA) with the contrast-filled catheter as reference for 
calibration. Coronary blood flow (CBF) was calculated by use of APV and vessel diameter 
(CBF = πr2(½APV)) 74. Flow mediated dilatation (FMD) was calculated comparing mean 
diameter in a 10 mm segment of the study vessel proximal to the infusion catheter tip during 
saline infusion and during hyperaemia induced by adenosine infusion. 
Coronary vascular function was assessed by CBF measurements at each step and 
proximal coronary FMD at maximum hyperaemic flow. Also, as a measure of endothelial 
function, response to acetylcholine infusion was calculated as percent increase in CBF at each 
dose of acetylcholine compared to baseline CBF. 
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igure 5. Doppler measurements. Average peak velocity (APV) at basal conditions (left), and at maximal 
tatistical methods 
inuous variables are reported as means (SD) and categorical 
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hyperaemia (right). 
 
 
S
Summary measures for cont
variables as proportions (%). ANOVA was used for comparison of continuous variables 
between treatment groups and Chi-Square Test for comparison of proportions. Skewed da
like plasma concentration of tHcy and metabolites, and even more for inflammatory markers,
are presented as medians with ranges and comparison between groups is done with Kruskal-
Wallis Test or Mann-Whitney U-test. Alternatively, logarithmic transformation is done. 
Associations were assessed by Pearson correlation coefficients, Spearman rank 
tion and linear regression. Paired sample t-test or Wilcoxon signed rank test were
for comparison within groups, and repeated measures ANOVA for comparison between 
groups, over time. Statistical package SPSS 11.0 – 13.0 was used. In paper 4, differences
time trends of flow (change during follow-up) by treatment were analysed by a linear mixed-
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effect model with random intercept on subject level (S-PLUS 7.0 for Windows). A two-tailed
P < 0.05 was considered statistical significant. 
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with the principles of the Declaration of Helsinki and approved by the Regional Committee 
for Medical Research Ethics. The study medication was approved by the Norwegian 
Medicines Agency and the data registration was approved by the Data Inspectorate. 
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Paper 1 
In WENBIT
treatment. To ensure rapid effect, our regimen also includes a high additional folic acid 
of 5 mg/day given for the first two weeks. This loading dose caused an immediate tHcy 
response with a significant reduction at three days, and a maximum reduction of 31% wa
reached within two weeks. Also, the effect was maintained for at least six months despite th
low long-term dose. The dose required for effective and safe tHcy reduction during long-term 
supplementation for years has been debated, and there are safety concerns about daily doses 
above 1 mg, since high doses may lead to free folic acid in serum 75. A high folic acid dose o
2 – 5 mg is used in many ongoing trials 76, probably because such a dose may have additional 
tHcy reducing effects in some patients, such as those with renal impairment 77. We could 
demonstrate a significant reduction of tHcy within 3 days, and a long-term effect of the 0.8
mg dose later confirmed effective in meta-analysis 65. 
Our study confirms previous reports that treatm
l tHcy 64,78 but caused a significant reduction in PML tHcy 79,80. In our patients, the 
vitamin B6 effect on PML tHcy was independent of and added to the effect of the folic 
acid/B12 combination. The most striking effect of the B6 supplementation was a rapid a
pronounced reduction in the plasma cystathionine levels. Vitamin B6 treatment eliminated 
high levels of cystathionine after methionine loading with no change in PML methionine. O
findings are in agreement with published data showing that cystathionine levels are elevated 
in patients with B vitamin deficiency 81,82, that a triple combination with folic acid, B12 and 
B6 lowers basal cystathionine concentrations in elderly people 78, and that vitamin B6 alone 
lowers basal as well as PML cystathionine levels in both healthy and vitamin B6 deficient 83. 
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 through the BHMT reaction buffers and tends to 
reduce ves 
ecause 
 
aper 3 
nt sub study of WENBIT, we evaluated the effect of B-vitamin intervention on 
The vitamin B6 effect on cystathionine levels probably reflect an enhanced activity of the 
cystathionine-γ-lyase which is known to be very sensitive to PLP depletion 83-85. In our stud
population, we found that only vitamin B6 treatment influences cystathionine levels, 
suggesting that cystathionine levels may be a unique marker for identifying subjects th
respond to vitamin B6 intervention. 
 
P
The median
earlier reports 86, with a remarkable stable level throughout the observation period, except
a transient increase after methionine loading. Methionine loading, a situation that maximally 
challenges the methionine-homocysteine pathways, was done at baseline and after 3 months. 
At baseline we found a strong inverse association between PML betaine and PML increase in 
tHcy, and somewhat weaker association between basal betaine and PML increase in tHcy. 
After B-vitamin treatment, PML increase in tHcy was reduced, its inverse relation to betain
weakened and was essentially abolished in patients receiving folic acid/vitamin B12. Our data
is in concordance with a betaine supplementation study, which show a reduced PML tHcy 
after oral betaine supplementation 87. 
These data indicate that betaine
the homocysteine response during methionine excess. This reaction, which conser
the homocysteine carbon backbone, may be beneficial under conditions of limiting supply of 
folate required for the methionine synthase reaction. These findings emphasize the 
complementary relationship between betaine and folate metabolism. Furthermore, b
PML tHcy confers increased risk for occlusive vascular disease independent of fasting tHcy
88, betaine and related metabolites should be included in future studies of homocysteine and 
cardiovascular risk. 
 
P
In the curre
important biomarkers of atherogenesis, including neopterin, sCD40L, IL-6 and CRP. Prior 
investigations have not only indicated that tHcy is significantly related to many of these 
processes 38,89, but also indicate that folate and vitamin B6 are associated with CVD, 
independent from their relation with tHcy 69. 
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We found that neopterin is related to tHcy, even when renal function is corrected for. 
In multiple linear regression analyses with neopterin as dependent variable, and tHcy, GFR, 
LDL-cholesterol, folate, vitamin B6 and vitamin B12 as independent variables, predictors of 
neopterin were levels of tHcy (β=0.35, p<0.001), GFR (β=-0.37, p<0.001) and LDL-
cholesterol (β=0.34, p<0.001). Our observation of a particular strong relation between tHcy 
and neopterin, a marker of cellular immune response, corroborates results from several 
previous reports 90,91. After 6 months of treatment, the strong relation seen at baseline between 
tHcy and neopterin was no longer present in patients receiving folic acid and vitamin B12. 
This could suggest that an optimal folate status overrides the influence of immunostimulation 
on tHcy plasma levels. Our data further indicate that the utility of homocysteine as a predictor 
of CVD is limited to subjects not taking folic acid/vitamin B12 supplement. 
However, despite the fact that plasma tHcy was lowered by 33% by folate 0.8 mg 
combined with vitamin B12 0.4 mg, and that a high dose of vitamin B6 (40 mg) was given, no 
significant changes in the evaluated biomarkers, neopterin, sCD40L, IL-6 or CRP, were 
observed. Failure to reverse inflammatory processes associated with atherosclerosis may 
partly explain the negative results of B-vitamin intervention in patients with established CVD 
treated with conventional therapy. 
 
Paper 4 
In this trial, we have shown that two years of treatment with folic acid/vitamin B12 improved 
basal coronary blood flow and blood flow at maximum hyperaemia induced by adenosine. In 
contrast, folic acid/vitamin B12 did not improve coronary endothelial function as measured 
by flow-induced change in coronary vessel diameter or change in flow following stimulation 
with acetylcholine. Vitamin B6 treatment did not change any of the vascular function 
variables. 
Although the number of patients (n=40) may seem limited, this is the largest study on 
folate therapy and coronary vascular function. Most other studies on endothelial function and 
B-vitamins, have measured brachial FMD 41. Only one study on the effect of B-vitamins on 
coronary flow in patients with CAD has been published 92, with a total of 15 patients 
randomised to treatment with folic acid (5 mg/d) and vitamin B12 (0.4 mg/d) or placebo for 
six months. In that study, B-vitamin treatment was associated with a significant improvement 
in acetylcholine-induced coronary blood flow. It is noteworthy that these patients had 
relatively high baseline tHcy (17.9 µmol/L), few patients received statin therapy, and a high 
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dose of folic acid was used. In contrast, we found an effect of folic acid/vitamin B12 on basal 
and maximal hyperaemic coronary blood flow, but no effect on acetylcholine stimulated flow. 
The reported relations between folate or tHcy levels and brachial endothelial-
dependent FMD are somewhat conflicting 93. However, most studies suggest that a rapid 
increase in plasma tHcy levels, as observed during methionine or homocysteine loading 
41,93,94, or after a protein rich meal 95, impairs brachial endothelial function, while high doses 
of folic acid improve endothelial function, possibly partly independent of its homocysteine-
lowering effect41,96. The mechanism by which homocysteine impairs endothelial function may 
involve homocysteine-induced reduction of intracellular tetrahydrobiopterin, thereby causing 
eNOS-uncoupling 97. Folic acid, through its circulating form, 5-methyltetrahydrofolate, is 
believed to enhance regeneration of tetrahydrobiopterin and improve eNOS-coupling and 
thereby improve endothelial function independently of homocysteine 98,99. Recent data from 
an isolated rat heart model supports our findings of increased coronary flow by folic acid 
treatment, and suggests a mechanistic role of NO 100. 
Whereas NO is an established regulator of vascular tone, there is some evidence that 
endothelium-derived hyperpolarizing factor (EDHF) plays a major role in regulating 
microcirculation 101. In renal microcirculation of rats, EDHF-mediated vasodilatation is 
impaired during methionine loading and partly restored by 5-methyltetrahydrofolate 102. This 
suggests an additional mechanism by which folic acid therapy in our patients has improved 
vascular tone and microcirculation, since resting coronary flow (CBF-basal) and maximal 
hyperaemia (CBF-ado) largely depend on microvascular dilatation in non obstructive 
coronary vessels 103. A beneficial effect on microvascular flow, together with reduced arterial 
stiffness 104, may explain a reduced frequency of electrocardiographic changes at exercise 
tests 105 and reduction in blood pressure 106 observed after treatment with folic acid. 
If long-term treatment with folic acid improves vascular function, this may have 
important clinical implications. and explain a reduction in stroke mortality rate observed in 
North America following folic acid fortification 107 and a reduction in stroke events in the 
HOPE-2 study 108. Prior studies have demonstrated that even minor reductions in blood 
pressure are associated with significant lower risk of stroke, but with less effect on ischemic 
heart disease 109. Thus, potential treatment effects of folic acid related to a reduction in blood 
pressure, may act differently upon risk of stroke and CAD 19,109. Notably, folic acid/B12 
therapy has not been associated with reduced risk of coronary events in any of the published 
randomised trials with B-vitamin intervention in patients with established CVD 110,111. 
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MAIN CONCLUSIONS 
1. The folic acid/vitamin B12 combination used in WENBIT provides a rapid, substantial 
and long-term tHcy lowering effect and significantly reduces PML tHcy. 
2. Vitamin B6 does not influence basal tHcy, but reduces PML tHcy. 
3. Vitamin B6 treatment markedly reduces basal and PML cystathionine levels. 
4. Folic acid and betaine are interchangeable methyl donors in homocysteine metabolism. 
5. Treatment with folic acid/vitamin B12 or vitamin B6 has no detectable effect on levels of 
neopterin, sCD40L, IL 6 or CRP, inflammatory markers, which are related to 
atherosclerosis. 
6. Treatment with moderate doses of folic acid in combination with vitamin B12 is 
associated with a significant increase in both basal and in adenosine-stimulated maximal 
coronary blood flow, reflecting improved vascular function. 
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FURTHER PERSPECTIVES 
Numerous studies demonstrate that hyperhomocysteinemia is related to an increased risk of 
the existence, extent, progression and prognosis of CVD 33,34. In contrast, in recent published 
trials, no significant effect on the primary outcome was documented in patients with stroke 
(VISP) 111, acute myocardial infarction (NORVIT) 110, CVD (HOPE-2) 108 or chronic renal 
failure (ASFAST) 112. A nearly significant increase of myocardial infarction was 
demonstrated in the NORVIT trial (in the group receiving both folic acid and vitamin B6) 110, 
whereas a significant reduction in stroke was demonstrated in HOPE-2 108. The latter finding 
is in accordance with a reduction in stroke mortality rate observed in North America 
following folic acid fortification 107. 
We have recently presented preliminary clinical data from WENBIT (ESC -07, 
M.Ebbing), which do not support a secondary preventive effect of B-vitamins in a population 
with CVD. Both the VISP and the ASFAST trials, and possibly WENBIT, were 
underpowered to detect clinical effects of the intervention of a magnitude similar to what 
might have been expected from the most recent epidemiological data 111,112. Thus, the results 
from these clinical trials still leave uncertainty of the possible role of homocysteine in the 
progression of atherosclerotic disease and further trials (WACS, SEARCH, PACIFIC, 
CHOAS-2, VITATOPS) must be completed. 
In addition, two randomised trials evaluating restenosis after PCI showed conflicting 
results 60,61. WENBIT will provide data on B-vitamins and restenosis after coronary stenting 
to further elucidate this question. 
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Changes in basal and postmethionine load concentrations of total
homocysteine and cystathionine after B vitamin intervention1–3
Øyvind Bleie, Helga Refsum, Per Magne Ueland, Stein Emil Vollset, Anne Berit Guttormsen, Ebba Nexo, Jørn Schneede,
Jan Erik Nordrehaug, and Ottar Nygård
ABSTRACT
Background: Vitamin B-6 is necessary for the metabolism of ho-
mocysteine and is often used in combination with folic acid and
vitamin B-12 in clinical trials that investigate whether the lowering
of plasma total homocysteine (tHcy) can prevent vascular disease.
Objective: We compared the effects of vitamin B-6 with the effects
of folic acid and vitamin B-12, as used in the Western Norway
B-vitamin Intervention Trial (WENBIT), on basal and postmethi-
onine load (PML) tHcy and cystathionine concentrations.
Design: Ninety patients with suspected coronary artery disease were
randomly assigned to 1 of 4 groups to receive daily oral treatment
with 1) 0.8 mg folic acid, 0.4 mg vitamin B-12, and 40 mg vitamin
B-6 (group A); 2) 0.8 mg folic acid and 0.4 mg vitamin B-12 (group
B); 3) 40 mg vitamin B-6 (group C); or 4) placebo (group D). For the
first 2 wk, groups A and B received additional folic acid (5 mg/d). A
methionine-loading test was performed at baseline and after 3 mo.
Results: Treatment with folic acid and vitamin B-12 caused a rapid
and significant lowering of basal (31%) and PML tHcy concentra-
tions (22%), with no effect on cystathionine. Vitamin B-6 did not
change basal tHcy and had a significant but limited effect on PML
tHcy concentrations. However, vitamin B-6 treatment markedly
lowered basal and PML cystathionine by 31% and 42%, respec-
tively.
Conclusion: The folic acid and vitamin B-12 combination applied
in WENBIT provides rapid, substantial, and long-term tHcy-
lowering effects, whereas the effect of vitamin B-6 on tHcy was
relatively small and confined to PML tHcy. However, vitamin B-6
treatment caused a marked reduction in plasma cystathionine. Cys-
tathionine could be a useful marker for assessment of the vitamin B-6
effect and should, together with tHcy, be related to clinical outcome
in ongoing trials. Am J Clin Nutr 2004;80:641–8.
KEY WORDS Homocysteine, cystathionine, folate, vitamin
B-6, vitamin B-12, vascular disease, methionine loading
INTRODUCTION
Epidemiologic and experimental evidence suggest that the
concentration of total homocysteine (tHcy) is an independent and
important risk factor for cardiovascular disease (CVD) (1–4).
The precise underlying mechanism is, however, unknown (5, 6).
Some data suggest that important determinants of the tHcy con-
centration, such as folate and vitamin B-6, could be associated
with CVD and vascular function independently of the tHcy con-
centration (7–10).
Most studies on tHcy and CVD involve measurement of tHcy
in the fasting or basal state. Measuring the concentration of tHcy
after methionine loading could identify additional people with
hyperhomocysteinemia (11). Data from cross-sectional studies
indicate that postmethionine load (PML) hyperhomocysteine-
mia predicts risk of CVD independently from fasting or basal
tHcy concentrations (2, 12). Prospective cohort studies that eval-
uate the predictive role of PML tHcy, however, have not been
performed.
The tHcy concentration can be effectively lowered by B vita-
mins. A 25% reduction is achieved by a low daily dose of 0.4–0.5
mg folic acid (13). Oral treatment with vitamin B-12 or vitamin
B-6 could have some effect in selected subjects (14, 15), and
vitamin B-6 reduces the PML increase in tHcy (16).
Several large-scale clinical trials were initiated to test whether
lowering tHcy prevents (recurrent) occlusive vascular disease
(17). Results from one trial were published and suggest that tHcy
lowering decreases the incidence of cardiovascular events after
coronary angioplasty (18). A combination of folic acid, vitamin
B-6, and vitamin B-12 was used in this study, and such triple
combinations are used in most of the other ongoing tHcy-
lowering trials (17). Notably, these B vitamins influence other
metabolic pathways in addition to homocysteine. Vitamin B-6
alone acts as a cofactor of more than 100 different reactions (19).
If trials with the triple combinations turn out positive, it could,
therefore, be controversial to what extent a reduction in homo-
cysteine itself could account for vascular and clinical effects, at
least from a mechanistic point of view.
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The current investigation is part of the Western Norway
B-vitamin Intervention Trial (WENBIT) and was designed to
evaluate acute and long-term effects of the intervention on tHcy
and related metabolites in the basal state and after repeated me-
thionine loading. The 2  2 factorial design of folic acid and
vitamin B-12 combination and vitamin B-6 is similar to that
applied in the other Norwegian tHcy-lowering trial, NORVIT.
This design allows us to investigate the separate biochemical
effects of both folic acid and vitamin B-12 combination and
vitamin B-6.
SUBJECTS AND METHODS
Patients and recruitment
WENBIT is a prospective, randomized, double-blind study on
the effects of tHcy-lowering therapy on mortality and cardiovas-
cular events. Adult patients (18 y) undergoing coronary an-
giography for suspected coronary artery disease or aortic valvu-
lar stenosis are eligible, independent of subsequent therapy.
Exclusion criteria are malignant disease, alcohol abuse, mental
illness, reluctance to long-term follow-up, and participation in
other clinical trials. Recruitment to the main study started in 2000
and finished March 2004 with the aim of 3000 included patients.
The present study examined the biochemical response to B
vitamin intervention in a total of 90 consecutive patients (Table
1) recruited at Haukeland University Hospital in the period of
April 1999 to September 1999. Written informed consent was
obtained from all patients. The study protocol was approved by
the regional ethics committee and by the Norwegian Medicines
Agency.
Follow-up was not complete. One patient died after the visit at
1 mo, and 2 patients withdrew their consent after 3 d and 1 mo,
respectively. A total of 81 patients (90%) attended the second
methionine-loading session at 3 mo, and 74 patients (82%) at-
tended all 6 sessions.
Study design
With use of a 2  2 factorial block design, the recruited
patients were randomly assigned into 4 groups for daily oral
treatment: group A received folic acid (0.8 mg), vitamin B-12
(cyanocobalamin; 0.4 mg), and vitamin B-6 (40 mg); group B
received folic acid and vitamin B-12; group C received vitamin
B-6; and group D received placebo. For the first 2 wk, the folic
acid groups (A and B) received an additional loading dose of folic
acid (5 mg/d); the other 2 groups (C and D) received additional
placebo capsules. All capsules, both for long-term treatment (red
capsules) and for the loading period (white capsules), contained
0.4 mg silica, 0.7 mg magnesium stearate, and 56.8–138.9 mg
lactose monohydrate capsulated in gelatin. Capsules were col-
ored red with 0.2 mg azorubin and 0.6 mg titanium dioxide or
white with 1.0 mg titanium dioxide. Packages of trial capsules
were prepared and given serial numbers in random order in
blocks of 20 by Alpharma A/S (Copenhagen).
Patient data were collected from patient-administered ques-
tionnaires, and a full routine medical examination was done at
baseline before vitamin therapy started. Coronary angiography
was performed 3 d later.
Blood collection and biochemical analyses
Nonfasting (basal) blood samples were collected at baseline
and after 3 d, 2 wk, 1 mo, 3 mo, and 6 mo of B vitamin interven-
tion. Times since last meal and last big meal were noted. An oral
methionine-loading test (0.1 g/kg body weight) was done at base-
line and after 3 mo. PML blood samples were drawn 4 h after
methionine intake (20).
Routine blood analyses, including hematologic indicators, re-
nal function markers, and lipid-related factors, were analyzed at
TABLE 1
Characteristics of the study population at baseline by total group and treatment category
Total group
(n 90)
Treatment groups P1
A: folic acid
 B-12 B-6
(n 22)
B: folic acid
 B-12
(n 23)
C: B-6
(n  21)
D: placebo
(n 24)
All
groups
Groups A
B vs groups
C D
Groups A
C vs groups
B D
Age (y) 61.5 9.82 62.0 10.3 58.8 9.1 63.0 8.8 62.5 11.0 0.48 0.23 0.39
Women (%) 23 27 13 33 21 0.43 0.46 0.14
Ever smokers (%) 83 77 96 71 86 0.14 0.40 0.03
Diabetes (%) 7 9 5 10 4 0.83 0.82 0.44
Prior myocardial
infarction (%)
60 68 57 62 54 0.79 0.67 0.35
Prior revascularization (%) 34 36 35 14 50 0.10 0.83 0.09
BMI (kg/m2) 26.5 3.7 26.3 2.7 27.2 3.7 25.9 3.6 26.5 4.6 0.73 0.52 0.35
Systolic blood pressure
(mm Hg)
145 20.0 141 16.2 147 19.5 139 18.4 150 23.8 0.20 0.75 0.04
Diastolic blood pressure
(mm Hg)
82 9.6 81 8.7 85 8.9 79 8.0 84 11.6 0.18 0.47 0.04
Total cholesterol (mmol/L) 5.6 1.5 5.4 1.3 5.4 0.7 5.7 1.5 5.8 2.2 0.77 0.30 0.87
LDL cholesterol (mmol/L) 3.5 1.4 3.4 1.1 3.4 0.7 3.6 1.3 3.8 2.1 0.78 0.33 0.80
HDL cholesterol (mmol/L) 1.18 0.33 1.19 0.34 1.13 0.30 1.29 0.41 1.13 0.26 0.35 0.54 0.12
Triacylglycerol (mmol/L) 1.90 0.90 1.82 1.06 1.99 0.78 1.85 0.95 2.02 0.84 0.85 0.86 0.37
Creatinine (mol/L) 96 19.1 91 11.4 96 9.5 90 12.6 104 31.0 0.04 0.29 0.02
1 One-factor ANOVA across and between groups.
2 x  SD (all such values).
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the central laboratory of the Haukeland University Hospital, with
use of Technicon Chem 1 (Bayer, Leverkusen, Germany) and
CELL-DYN 4000 (Abbot, Abbott Park, IL) platforms.
Blood samples containing EDTA for analysis of vitamins,
tHcy, and metabolites were immediately placed on ice, centri-
fuged within 30 min, and stored at 80 °C until further ana-
lyzed.
Plasma tHcy, total cysteine, and methylmalonic acid (MMA)
were determined with use of a modification of a gas chromatog-
raphy–mass spectroscopy (GC-MS) method that involves ethyl-
chloroformate derivatization as described by Husek (21). Cys-
tathionine (and tHcy) was determined with use of a tandem mass
spectrometry method (AB Guttormsen, H Refsum, E Solheim,
unpublished observations, 1998). Briefly, after addition of re-
ductant and deuterated standards (cystathionine and homocys-
tine), the sample was acid precipitated and the supernatant fluid
was injected on a reversed-phase column. The sulfur amino acids
were eluted with use of an ethanol gradient in acetic acid, then
detected, and quantified with use of the transition from the pre-
cursor to the product ion for each of the amino acids and their
deuterated standards. The between-day CV for cystathionine is
between 5% and 10%, depending on the concentration. Plasma
tHcy was also determined with use of a fluorescence polarization
immunoassay adapted to the Abbot IMx analyzer (Abbot Labo-
ratories, Abbott Park, IL) (22). Both tandem mass spectroscopy
(r 0.94) and IMx (r 0.95) methods correlated well with the
GC-MS method. On the basis of an evaluation of the data with use
of Bland-Altmann plots (23), the tHcy concentrations measured
by the GC-MS method are reported.
Folate and cobalamin were determined by microbiologic as-
says with use of a chloramphenicol-resistant strain of Lactoba-
cillus casei and colistin sulfate–resistant strain of Lactobacillus
leichmannii, respectively (24, 25). Both the folate and cobalamin
assays were adapted to a microtiter plate format (26) and carried
out by a robotic workstation (Microlab AT plus 2; Hamilton,
Bonadus AG, Switzerland). Plasma concentrations of pyridoxal
5-phosphate (PLP), pyridoxal, pyridoxine, and 4-pyridoxic acid
were analyzed by an ion-pair reversed-phase chromatography
(27). Data on these B-6 vitamers are reported in a separate paper
(28); plasma concentrations of PLP are used in this report.
Statistical analysis
Summary measures for continuous variables are reported as
means and categorical variables as proportions (%). Vitamin and
metabolite data were logarithmically transformed before further
analysis and are presented as geometric mean. Associations were
assessed by Pearson correlation coefficients. Analysis of vari-
ance (ANOVA) was used for comparison of continuous variables
between treatment groups at baseline. Possible interaction of
folic acid and vitamin B-12 combination and vitamin B-6 treat-
ments was tested by repeated measures ANOVA. When the treat-
ment effect of either folic acid or vitamin B-6 was studied, the 2
patient groups with and without active treatment were combined
if no significant interaction was observed. A 2-tailed P  0.05
was considered statistically significant. Data were analyzed with
use of SPSS 11.0 (SPSS Inc, Chicago).
RESULTS
Among the 90 patients aged 38–80 y (21 women and 69 men),
22 patients were randomly assigned to folic acid, vitamin B-12,
and vitamin B-6 (group A); 23 patients to folic acid and vitamin
B-12 (group B); 21 patients to B-6 alone (group C); and 24
patients to placebo (group D) (Table 1). The groups were well
matched, but creatinine, tHcy, and MMA concentrations were
somewhat higher in the placebo group (Table 1 and Table 2).
We observed no significant interaction of the folic acid and
vitamin B-12 combination and vitamin B-6 treatments for any of
the vitamins or metabolites studied (plasma folate, P  0.9;
blood folate, P  0.07; plasma cobalamin, P  0.3; plasma
MMA, P  0.4; plasma tHcy, P  0.1; plasma cystathionine,
P0.4). Consequently, the 2 patient groups with and without the
TABLE 2
Baseline values of B vitamins, total homocysteine (tHcy), and related metabolites before treatment1
Total group2
(n 90)
Treatment groups2 P3
A: folic acid
B-12 B-6
(n 22)
B: folic acid
B-12
(n 23)
C: B-6
(n 21)
D: placebo
(n 24)
All
groups
Groups A
B vs groups
C D
Groups A
C vs groups
B D
Plasma folate (nmol/L) 8.3 (3.1–22.3) 8.8 (3.3–23.8) 7.5 (3.0–18.7) 8.6 (3.3–22.8) 8.4 (2.8–25.2) 0.73 0.68 0.39
RBC folate (nmol/L) 263 (126–547) 257 (111–591) 282 (125–637) 249 (130–477) 263 (139–501) 0.73 0.55 0.36
Cobalamine (pmol/L) 373 (177–788) 359 (234–552) 388 (222–678) 403 (170–954) 349 (129–945) 0.56 0.99 0.67
Vitamin B-6, PLP
(nmol/L)
24.4 (7.6–78.7) 22.1 (8.3–59.3) 26.1 (6.8–101.2) 24.1 (6.2–93.9) 25.4 (9.4–68.5) 0.80 0.83 0.38
tHcy (mol/L) 11.1 (6.4–19.4) 10.1 (6.8–15.2) 11.7 (7.7–17.8) 10.3 (5.9–17.7) 12.3 (6.0–25.3) 0.05 0.52 0.01
PML tHcy
(mol/L)
31.3 (19.0–51.8) 29.4 (17.4–49.7) 31.8 (22.5–45.0) 29.3 (18.2–47.4) 34.8 (19.5–62.1) 0.08 0.38 0.02
MMA (mol/L) 0.16 (0.07–0.36) 0.16 (0.08–0.31) 0.14 (0.07–0.29) 0.14 (0.09–0.21) 0.19 (0.06–0.60) 0.03 0.28 0.19
Cystathionine (mol/L) 0.31 (0.09–0.99) 0.26 (0.07–0.93) 0.28 (0.11–0.70) 0.33 (0.08–1.45) 0.36 (0.14–0.93) 0.24 0.05 0.57
PML cystathionine
(mol/L)
2.90 (0.73–11.5) 2.57 (0.65–10.1) 2.45 (0.78–7.67) 3.49 (1.04–11.8) 3.25 (0.62–16.9) 0.26 0.05 0.72
Cysteine (mol/L) 292 (227–376) 282 (218–366) 287 (239–345) 298 (240–369) 301 (219–414) 0.29 0.06 0.57
PML cysteine (mol/L) 279 (216–361) 264 (216–323) 277 (224–344) 281 (217–363) 294 (217–398) 0.05 0.03 0.08
1 RBC, red blood cell; PLP, pyridoxal 5-phosphate; PML, postmethionine load; MMA, methylmalonic acid.
2 Geometric x; geometric reference range of population in parentheses (antilog: mean log-tHcy 1.96 SD).
3 One-factor ANOVA across and between groups.
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actual vitamins were pooled in the analysis of changes over time
(Figure 1).
Vitamin status
Mean plasma folate concentrations increased from 8.1 nmol/L
to a peak concentration of 334 nmol/L at day 3 and remained
elevated for the next 6 mo (57.0 nmol/L) in the combined group
of patients treated with folic acid (groups A and B). Blood folate
concentration was significantly increased after 3 d (from 269
nmol/L to 486 nmol/L, P0.001) and continued to increase over
the next 6 mo (to 996 nmol/L, P  0.001). No change in folate
status was observed in the groups not treated with folic acid
(Figure 1).
Mean plasma cobalamin was significantly increased already at
day 3 in the groups (A and B) treated with vitamin B-12 (from 374
pmol/L to 448 pmol/L, P  0.001), and a moderate additional
increase was observed during the next 6 mo (to 546 pmol/L, P
0.001; Figure 1). Further details on vitamin B-12 and fluctuations
in its binding proteins were reported in a separate paper (29).
After vitamin B-6 treatment, concentrations of PLP were in-
creased 10-fold within 3 d, and PLP remained at this concentra-
tion during the observation period. The responses of the different
B-6 vitamers were described in a separate paper (28).
Methylmalonic acid, homocysteine, and cystathionine
Overall, the vitamin B-12 treatment caused no significant
change in MMA during the study (Figure 1). Eight patients had
elevated MMA 0.28 mol/L at baseline. Only one patient [in
group D (placebo)] had plasma cobalamin200 pmol/L and was
classified as vitamin B-12 deficient (MMA, 0.77 mol/L;
plasma cobalamin, 117 pmol/L). Vitamin B-12 injections were
started after 3 mo, and a decline in MMA to 0.15 mol/L was
observed 3 mo later. Four subjects receiving vitamin B-12 (group
A or B) had marginally elevated MMA (0.32 mol/L). Three
of them responded with 	50% reduction in MMA within the
next few months. However, 1 of the 3 subjects not receiving
vitamin B-12 experienced a marked decline in MMA.
Treatment with folate and vitamin B-12 (in groups A and B)
was associated with a significant 14% reduction (1.5 mol,
P 0.001) in plasma tHcy by day 3. The full effect was obtained
after 2 wk with 31% reduction (3.3 mol, P 0.001). There-
after, no further reduction was observed, and tHcy remained at
this low concentration (Figure 1). Repeated measures ANOVA
confirmed a significant effect of treatment across the entire pe-
riod (P 0.001). The degree of reduction in tHcy observed after
3 mo was strongly related to initial concentrations of plasma tHcy
(r  0.775, P  0.001) and plasma folate (r  0.478, P 
0.001). Cumulative frequency plots show reduction in tHcy by
folate and vitamin B-12 treatment compared with the groups
given vitamin B-6 or placebo over the whole tHcy distribution,
but more pronounced effect at high concentrations (Figure 2,
upper left panel).
Vitamin B-6 treatment had no effect on basal tHcy concentra-
tion but was associated with a significant 14% decrease (0.042
mol/L, P 0.03) in basal plasma cystathionine already at day
3. Maximum reduction of 31% (0.090mol/L, P 0.001) was
reached at 3 mo and correlated strongly with cystathionine con-
centrations before treatment (r  0.95, P  0.001). Repeated
measures ANOVA verified a significant reduction of plasma
cystathionine by intervention throughout the entire treatment
FIGURE 1. Geometric mean changes in vitamin and metabolite concentrations during 6 mo of B vitamin supplementation. Error bars represent 95% CIs.
Only patients attending all 6 sessions are included in these analyzes (n 74). The 2 patient groups with and without the actual vitamins were combined in the
analysis when the treatment effect of either combination of folic acid and vitamin B-12 [groups AB (n40) compared with groups CD (n34)] or vitamin
B-6 [groups A C (n 36) compared with groups B D (n 38)] was studied because there were no significant interactions. Regimens containing folic
acid and vitamin B-12 had significant effects on plasma folate (P  0.001), blood folate (P  0.001), plasma cobalamin (P  0.001), and plasma total
homocysteine (tHcy) (P  0.001) but not on plasma methylmalonic acid (MMA) (P  0.18), whereas vitamin B-6 had significant effects on plasma
cystathionine (P 0.001) by repeated-measures ANOVA.
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period (P 0.005). We observed no significant change in basal
cystathionine concentrations by folic acid and vitamin B-12 or
placebo (Figure 1). Cumulative frequency plots of cystathionine
with and without vitamin B-6 treatment demonstrated that vita-
min B-6 affected the whole range of cystathionine concentrations
and displaced the distribution curve to the left (Figure 2, bottom
left panel).
Methionine, homocysteine, and cystathionine after
methionine loading
Vitamin treatment had no influence on basal plasma methio-
nine or the increase in methionine observed after methionine
loading (from 183.4mol/L to 659104mol/L at baseline;
from 22 4.8 mol/L to 661 105 mol/L after 3 mo).
At baseline, both PML tHcy and the increase in tHcy after
methionine loading (PML tHcy) were strongly related to basal
tHcy concentrations (r0.739, P0.001; r0.439, P0.001,
respectively). After 3 mo of treatment, PML tHcy was signifi-
cantly reduced compared with baseline, both in group B treated
with folic acid and vitamin B-12 (22%; P 0.001) and in group
C treated with vitamin B-6 (10%; P 0.02). The greatest reduc-
tion was observed in group A treated with all vitamins (27%;
P  0.001; data not shown). Comparable response to vitamin
treatment was seen for PML tHcy (Table 3). The cumulative
frequency plots of PML tHcy after 3 mo (Figure 2, upper right
panel) illustrate that folic acid and vitamin B-12 treatment was
associated with a shift of the PML tHcy distribution to the left
compared with vitamin B-6 or placebo.
Similar to tHcy, baseline PML cystathionine and  PML cys-
tathionine were strongly related to the basal concentration (r 
0.578, P  0.001; r  0.567, P  0.001, respectively). The
associations were attenuated by vitamin B-6 treatment and no
longer significant after 3 mo (r  0.143, P  0.39; r  0.005,
P 0.98, respectively). Overall, vitamin B-6 treatment for 3 mo
reduced PML cystathionine by 42% andPML cystathionine by
44% compared with baseline, whereas folate and vitamin B-12
had no such reducing effect (Table 3). The cumulative frequency
plot of PML cystathionine (Figure 2, bottom right) after 3 mo of
intervention illustrates the ability of vitamin B-6 treatment to
suppress high PML cystathionine concentrations.
DISCUSSION
We studied the plasma concentrations of tHcy and a panel of
related biochemical markers before and during treatment with a
B vitamin intervention regimen that is currently used in 2 Nor-
wegian clinical trials. Frequent initial blood sampling enabled us
to study the early effects, and the influence on metabolite con-
centrations after methionine loading was re-investigated after 3 mo.
Unlike most other ongoing clinical trials (17), the present study used
a 2  2 factorial design, which also allowed us to discriminate
between the effects of folic acid and vitamin B-12 combination and
vitamin B-6 on the concentration of metabolites.
Previous studies have shown that daily supplementation with
0.5–5 mg folic acid leads to a reduction in tHcy of about 25%
(14). The dose required for effective and safe tHcy reduction
during long-term supplementation for years is, however, de-
bated, and there are safety concerns about daily doses 1 mg
(30). A high folic acid dose of 2–5 mg is used in many ongoing
trials (17), probably because such a dose can have additional
FIGURE 2. Cumulative frequency plots of plasma total homocysteine (tHcy) and plasma cystathionine after 3 mo of B vitamin intervention (n 81). The
effectiveness of folic acid and vitamin B-12 (n 41) in reducing both high and low basal plasma and postmethionine load (PML) tHcy compared with vitamin
B-6 alone or placebo (n 40) is shown in the upper panels. The effect was particularly pronounced in subjects with high baseline values. Likewise, the plots
for cystathionine and PML cystathionine illustrate the effectiveness of vitamin B-6 (n  38) in reducing especially high concentrations of cystathionine
compared with the concentrations observed in subjects given folic acid and vitamin B-12 in combination or placebo (n 43).
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tHcy-reducing effects in some patients, such as patients with
renal impairment (31).
In WENBIT and NORVIT, a relatively low daily dose of folic
acid of 0.8 mg was chosen for long-term treatment. A recent
meta-analysis confirms that 0.8 mg is sufficient to obtain maxi-
mal tHcy-reducing effect in most subjects (32). To ensure rapid
effect, our regimen also includes a high additional folic acid dose
of 5 mg/d given for the first 2 wk. This loading dose caused an
immediate tHcy response with a significant reduction at 3 d, and
a maximum reduction of 31% was reached within 2 wk. Also, the
effect was maintained for at least 6 mo despite the low long-term
dose.
Because folic acid therapy can mask symptoms of vitamin
B-12 deficiency by correcting the megaloblastic anemia but al-
lowing the neuropathy to develop (33), vitamin B-12 was added
mainly for safety reasons (34). The daily requirement of cobal-
amin is only 2–6 g, but in patients with pernicious anemia
intrinsic factor is missing and cobalamin is not absorbed (35).
About 1% of a high oral dose is absorbed by passive diffusion
independent of intrinsic factor; hence, 0.4 mg was considered
adequate for the prevention of vitamin B-12 deficiency (36). We
observed increasing plasma cobalamin concentrations already at
day 3. No associated decline in mean MMA was observed, but no
patient except one (in the placebo group) was considered vitamin
B-12 deficient. Three subjects with marginally elevated MMA
responded with a reduction of MMA concentrations on vitamin
B-12 treatment, suggesting that this oral B-12 treatment is suf-
ficient to normalize MMA. However, larger studies are neces-
sary to document the effect of such a low-dose treatment of oral
vitamin B-12 on MMA status. Previous studies have shown that
vitamin B-12 can add to the tHcy-lowering effect of folic acid
(14). Because of the design, a potential tHcy-lowering effect of
vitamin B-12 cannot be assessed in the present study.
Vitamin B-6 is independently associated with the risk of CVD
(9). It is, however, not known how and whether vitamin B-6 is
causally related to CVD, and the dose required is uncertain. In our
study, vitamin B-6 was given in a relative high dose of 40 mg/d.
This dose is available over the counter in Norway, and it is
considered nontoxic (37). The theoretical basis for including
vitamin B-6 is that PLP is required by the enzymes cystathionine
-synthase and cystathionine--lyase that catalyze the transsul-
furation of homocysteine by way of cystathionine to cysteine
(38). In a rat model, however, vitamin B-6 deficiency is associ-
ated with both decreased remethylation and transsulfuration
(39). Population-based observational studies revealed associa-
tions between vitamin B-6 status and plasma tHcy (40, 41). In
contrast, treatment studies with vitamin B-6 suggest that the
effect on basal tHcy concentrations is modest or absent (14,
42–45).
Our study confirms previous reports that treatment with vita-
min B-6 had no significant effect on basal tHcy (42–46) but
caused a significant reduction in PML tHcy (47, 48). In our
patients, the vitamin B-6 effect on PML tHcy was independent of
and added to the effect of the folic acid and vitamin B-12 com-
bination. The most striking effect of the vitamin B-6 supplemen-
tation was a rapid and pronounced reduction in the plasma cys-
tathionine concentrations. Vitamin B-6 treatment eliminated
high concentrations of cystathionine after methionine loading
with no change in PML methionine. Our findings are in agree-
ment with published data showing that cystathionine concentra-
tions are elevated in patients with B vitamin deficiency (49, 50);
that a triple combination with folic acid, vitamin B-12, and vi-
tamin B-6 lowers basal cystathionine concentrations in elderly
people (43); and that vitamin B-6 alone lowers basal as well as
PML cystathionine concentrations in both healthy and vitamin
B-6–deficient subjects (51). The vitamin B-6 effect on cystathi-
onine concentrations probably reflect an enhanced activity of the
cystathionine--lyase, which is known to be very sensitive to
PLP depletion (39, 51, 52). In our study population, we found that
only vitamin B-6 treatment influences cystathionine concentra-
tions, suggesting that cystathionine concentrations could be a
unique marker for identifying subjects that will respond to vita-
min B-6 intervention.
Methionine intake causes an increase in S-adenosylmeth-
ionine, which is known to stimulate the transsulfuration pathway
by activating cystathionine -synthase (38) and thereby the syn-
thesis and excretion (53) of cystathionine. In line with this pro-
cess, we found that cystathionine was increased 10-fold after
methionine loading. The relative increase in cystathionine was
TABLE 3
Increases in total homocysteine (tHcy) and cystathionine after methionine loading and before and after 3 mo of B vitamin intervention1
Treatment groups
A: folic acid B-12 B-6
(n 21)
B: folic acid B-12
(n 20)
C: B-6
(n 18)
D: placebo
(n 22)
PML tHcy2 mol/L
Before 19.0 (16.4–22.0) 19.7 (17.6–22.0) 18.4 (16.1–21.1) 21.6 (18.9–24.5)
After 3 mo3 14.4 (12.8–16.1) 16.6 (14.9–18.5) 15.8 (13.9–17.8) 21.9 (18.7–25.6)
PML cystathionine2
Before 2.13 (1.55–2.92) 2.02 (1.55–2.62) 2.80 (2.13–3.67) 2.58 (1.81–3.69)
After 3 mo4 1.39 (1.15–1.68) 2.61 (2.04–3.36) 1.38 (1.14–1.66) 2.88 (1.94–4.29)
1 Geometric x in natural units; geometric reference range in parentheses (antilog: mean log-tHcy 1.96 SEM). PML, increase postmethionine loading.
2 There was no significant interaction between folic acid B-12 and B-6 treatment onPML tHcy or onPML cystathionine by repeated-measures ANOVA.
3 Main effect of folic acid B-12 (groups A B versus C D), P 0.006, and of vitamin B-6 (groups A C versus B D), P 0.015, on PML
tHcy by repeated-measures ANOVA.
4 Main effect of folic acid  B-12 (groups A  B versus C  D), P  0.7, and of vitamin B-6 (groups A  C versus B  D), P  0.001, on PML
cystathionine by repeated-measures ANOVA.
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much higher than the 3-fold increase observed for tHcy. Re-
cently, we found that an ordinary meal resulted in a 3-fold in-
crease of cystathionine, whereas tHcy did not increase signifi-
cantly (54). Hence, the cystathionine response to methionine
loading, the changes observed after an ordinary meal, and the
effect of vitamin B-6 treatment suggest that plasma cystathionine
is more sensitive than plasma tHcy to a changed flux from me-
thionine by way of homocysteine through the transsulfuration
pathway. This finding is supported by previous findings in sub-
jects fed a protein-rich diet depleted of vitamin B-6 in which
homocysteine was not detected in the urine until a marked in-
crease incystathionineexcretionhadoccurred(52).Thus, increased
cystathionine concentrations could reflect elevated intracellular
concentrations of homocysteine or increased conversion from ho-
mocysteine to cystathionine that is not associated with changes in
plasma tHcy concentrations. Because low vitamin B-6 intake and
PLP concentrations were associated with CVD risk (9, 55), future
studies should further evaluate elevated concentrations of cystathi-
onine as a possible marker of intracellular depletion of PLP or
intracellular increased tHcy.
In conclusion, we have shown that the folic acid and vitamin
B-12 combination used in 2 Norwegian clinical intervention
trials provides a rapid, substantial, and long-term tHcy-lowering
effect. Vitamin B-6 does not influence basal tHcy but reduces
tHcy after methionine loading. The most pronounced effect of
vitamin B-6, however, is a marked reduction in basal and PML
cystathionine concentrations. Cystathionine could serve as a
marker of intracellular vitamin B-6 depletion and relate vitamin
B-6 to clinical effects of homocysteine. The clinical implications
of these different metabolic effects should be evaluated in ongo-
ing trials.
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Paper II 

Betaine as a Determinant of Postmethionine Load Total
Plasma Homocysteine Before and After
B-Vitamin Supplementation
Pål I. Holm, Øyvind Bleie, Per M. Ueland, Ernst A. Lien, Helga Refsum,
Jan E. Nordrehaug, Ottar Nygård
Objective—Betaine is a substrate in the betaine–homocysteine methyltransferase reaction, converting homocysteine to
methionine. There are only sparse data on plasma betaine as a determinant of the plasma total homocysteine (tHcy)
concentration.
Methods and Results—Ninety patients undergoing coronary angiography were randomized into 4 groups administered
oral: (1) folic acid (0.8 mg), vitamin B12 (0.4 mg), and vitamin B6 (40 mg); (2) folic acid and vitamin B12; (3) vitamin
B6 alone; or (4) placebo. Nonfasting blood samples were collected at baseline and 3, 14, and 28 days and 3, 6, and 12
months after treatment start. A 4-hour methionine-loading test (0.1 g/kg) was performed at baseline and after 3 months.
At baseline, median (interquartile range) plasma betaine was 36.9 mol/L (range: 30.3 to 46.8) and was increased by
15% after methionine loading. The postmethionine load (PML) increase in tHcy was inversely related to plasma betaine
(0.29, P0.02) and even more strongly to PML betaine (0.47, P0.001). After 3 months of intervention, the
relation between the PML increase in tHcy and PML betaine was weakened (0.33, P0.007).
Conclusions—Plasma betaine is a strong determinant of the PML increase in tHcy in subjects not supplemented with
B-vitamins. (Arterioscler Thromb Vasc Biol. 2004;24:301-307.)
Key Words: betaine  homocysteine  folate  vitamin B12  vitamin B6
Homocysteine is an established risk factor for occlusivevascular disease.1 High plasma concentration is also
associated with impaired cognitive function, Alzheimer dis-
ease, adverse pregnancy outcomes, and congenital malforma-
tions, particularly neural tube defects.2
The plasma concentration of total homocysteine (tHcy) is
determined by a variety of physiological, lifestyle, and
genetic factors and disease states.3 Among these, renal
function, folate, and cobalamin status are particularly influ-
ential.4 The vitamin effects are explained by the functions of
5-methyltetrahydrofolate as substrate and cobalamin as co-
factor in the ubiquitous methionine synthase reaction, which
catalyzes the remethylation of homocysteine to methionine.5
Vitamin B6, however, has no6,7 or a moderate8,9 effect on
plasma tHcy.
Methionine loading, which involves measurement of tHcy
after a standard oral methionine dose, was originally designed
to reveal defects in the vitamin B6-dependent transsulfuration
pathway.10 Plasma postmethionine load (PML) tHcy has
since been associated with cardiovascular risk independent of
basal tHcy.11 Folate, as well as vitamin B6 status,9,11 are
significant predictors of PML tHcy. These vitamin effects in
humans are at variance with the idea, based on enzymological
data,5 animal,12 and human studies,6 that PML tHcy is
determined by the activity of vitamin B6-dependent enzyme,
cystathionine -synthase, whereas the folate-dependent ho-
mocysteine remethylation regulates basal tHcy.
Betaine (trimethylglycine) is obtained in small amounts
through the diet or is generated in liver and kidney from
choline through the sequential action of choline oxidase (EC
1.1.3.17) and betaine-aldehyde dehydrogenase (EC
1.2.1.8).5,13 Betaine serves as methyl donor of the zinc
metalloenzyme, betaine-homocysteine methyltransferase
(BHMT; EC 2.1.1.5). This enzyme is mainly confined to the
liver and kidney and catalyzes an alternative route of homo-
cysteine remethylation to methionine5 (Figure 1). The role of
betaine as a methyl donor explains the observations that
betaine supplementation reduces tHcy in homocystinurics14
and in healthy individuals.15–18 Betaine also attenuates the
tHcy increase after methionine loading in healthy subjects16,18
and in cardiovascular19 and renal patients.20 However, except
for a recent Canadian study reporting on an inverse relation
between fasting tHcy and betaine in cardiovascular patients,21
no study has addressed the question of the role of endogenous
betaine as a determinant of basal and PML tHcy.
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Using a newly developed liquid chromatography–tandem
mass spectrometry method,22 we investigated the association
between plasma betaine and tHcy before and after methionine
loading in 90 subjects. The subjects were enrolled in the
Western Norway B-Vitamin Intervention Trial (WENBIT)
and followed-up for 1 year of B-vitamin intervention as
implemented in this trial.
Methods
Subjects
We investigated 90 consecutive patients enrolled in the WENBIT, an
ongoing study on the effects of tHcy-lowering therapy on mortality
and cardiovascular events in 3000 patients. Eligible subjects were
adult patients (older than 18 years) undergoing coronary angiography
for suspected coronary artery disease or aortic valvular stenosis.
Exclusion criteria were malignant disease, alcohol abuse, mental
illness, patient unwillingness to participate in long-term follow-up,
and participation in other studies. The subjects were recruited at
Haukeland University Hospital from April 1999 to September 1999.
Informed consent was obtained from all patients. The study protocol
was approved by the regional ethics committee and Norwegian
Medicines Agency.
Protocol
Recruited patients were randomized into 4 groups in a 22 factorial
block design. Group FB (n22) was administered daily folic acid
(0.8 mg), vitamin B12 (cyanocobalamin, 0.4 mg), and vitamin B6
(pyridoxine, 40 mg). Group F (n23) was administered folic acid
and vitamin B12. Group B (n21) was administered vitamin B6.
Group P (n24) was administered placebo. For the first 2 weeks, the
groups (FB and F) receiving folic acid were administered an
additional loading dose of folic acid (5 mg/d). Packages of trial
tablets were prepared and given serial number in random order in
blocks of 20 by Alpharma A/S (Copenhagen, Denmark). Compliance
monitoring was accomplished by tablet counting and by determina-
tion of vitamin B concentrations in plasma.
The subjects underwent a full routine medical examination at
baseline before coronary angiography. Coronary angiography was
performed 3 days after starting vitamin therapy.
Blood Collection and Biochemical Analyses
Nonfasting (basal) blood samples were collected at baseline, after 3
days, at 2 and 4 weeks, and at 3, 6, and 12 months of B-vitamin
intervention. A methionine loading test (0.1 g/kg body weight) was
performed at baseline and after 3 months. PML blood samples were
drawn at 4 hours after loading. EDTA blood samples were immedi-
ately placed on ice, centrifuged within 30 minutes, and EDTA
plasma stored at 80°C until analysis.
Routine blood analyses, including serum creatinine, were analyzed
at the Central Laboratory of Haukeland University Hospital on
Technicon Chem 1 (Bayer, Leverkusen, Germany). The tHcy,23
betaine, choline, di-MethylGlyoxime (DMG),22 cobalamin24 plasma
folate,25 and pyridoxal phosphate26 were analysed by published
methods.
Statistics
Because of skewed distribution of values for tHcy and some
metabolites, data are presented as median values with interquartile
ranges. Associations between variables were evaluated by Spearman
rank correlation and multiple linear regression analyses. Variables
considered likely to influence the outcome parameters were included
in the multivariate models. Mann-Whitney U test or Kruskal-Wallis
test was used for between-group comparisons of continuous vari-
ables, and Wilcoxon signed rank test was performed for comparison
within groups at baseline and after 3 months. Data were analyzed
using SPSS 11.0 (SPSS Inc.).
Results
Subject Characteristics and Blood Indices
at Baseline
A total of 90 patients were included. Their median age was 62
years (range 38 to 80); 77% were males. Blood indices at
baseline for the whole study group are given in Table 1.
Median betaine was 36.9 mol/L and median PML betaine
was 44.5 mol/L. One patient (in group P) had plasma
cobalamin (117 pmol/L) below the lower reference limit (200
pmol/L), along with elevated MMA (0.77 mol/L), and was
considered cobalamin-deficient. Plasma folate was below the
lower reference limit (4.5 nmol/L) in 10 patients.
Table 1 also shows the expected marked increase in tHcy
and also a moderate increase in median betaine (15%;
P0.001), choline (7%; P0.001), and DMG (18%;
P0.001) after methionine loading.
The concentrations of basal and PLM betaine in particular,
but also of choline and creatinine, were markedly higher in
males than in females (Table 1). No parameters differed
significantly according to treatment group, except basal tHcy
(18% difference; P0.04) and basal choline (15%; P0.01)
and PML choline (21%; P0.04) (data not shown). Details
on plasma pyridoxal phosphate26 and cobalamin27 in this
population have been given in separate publications.
Figure 1. Betaine metabolism, homocysteine remethylation, and
transsulfuration. Ado indicates adenosine; AdoHcy,
S-adenosylhomocysteine; AdoMet, S-adenosylmethionine; BAD,
betaine aldehyde dehydrogenase; Bet, betaine; BHMT, betaine-
homocysteine methyltransferase; CBS, cystathionine
-synthase; CL, cystathionine lyase; CH3THF, methyltetrahydro-
folate; CO, choline oxidase; DMG, dimethylglycine; Cys, cys-
teine; Cysta, cystathionine; Hcy, homocysteine; MAT, methio-
nine adenosyltransferase; Met, methionine; MT,
methyltransferase; MTR, methionine synthase; SAHH,
S-adenosylhomocysteine hydrolase; THF, tetrahydrofolate.
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Simple Correlations at Baseline
Simple correlations at baseline are shown in Table 2. Baseline
tHcy was positively related to age, creatinine, and basal
DMG, and were inversely related to plasma folate and
cobalamin.
The increase in tHcy after methionine loading (PML
tHcy) was not related to the levels of B-vitamins. The PML
tHcy showed a strong inverse association with PML betaine
(r0.37, P0.001) and a moderate association with basal
betaine (r0.23, P0.03), as also depicted in Figure 2.
The concentrations of betaine, choline, and DMG, mea-
sured before and after loading (PML), were significantly and
positively correlated (Table 2; data for choline and DMG not
shown).
Determinants of Betaine, Choline,
and Dimethylglycine
We assessed age, gender, creatinine, and the B-vitamins as
predictors of basal betaine, choline, and DMG at baseline by
multiple linear regression (Table 3). Betaine showed a strong
relation to sex, whereas choline in particular, but also DMG,
was positively related to creatinine. The metabolites were not
significantly related to any B vitamin, ie, folate, cobalamin,
or vitamin B6 (Table 3). Betaine, choline, and DMG mea-
sured after methionine loading showed similar relations to
gender, age, creatinine, and the B-vitamins as observed for
the basal concentrations (data not shown).
Betaine as a Determinant of PML tHcy
The PML tHcy was inversely associated with basal betaine
(model I), PML betaine (model II) (Table 3), and the PML
increase in betaine (0.27, P0.02) by multiple linear
regression. PML betaine was a stronger predictor than basal
betaine of PML tHcy. The regression models also included
age, sex, creatinine, and the B-vitamins, and these factors
were not significantly related to PML tHcy (Table 3).
Additional adjustment for basal or PML choline and basal or
PML DMG in the respective models had no effect (data not
shown).
Betaine, Choline, and DMG According to Duration
and Type of Intervention
Figure 3 depicts plasma concentrations for choline, betaine,
and DMG measured at intervals from baseline to 12 months.
PML concentrations at baseline and after 3 months are
included. The levels for betaine in particular, but also for
choline and DMG, were higher in men than in women
TABLE 1. Subject Characteristics and Blood Indices at Baseline According to Gender*
Total n90 Men n69 Women n21 P Value†
tHcy, mol/L 11.0 (9.3–12.9) 11.4 (9.8–13.0) 9.6 (7.7–12.9) 0.09
PML tHcy, mol/L 31.3 (27.0–37.6) 30.6 (27.1–36.0) 32.1 (24.3–39.0) 0.9
Betaine, mol/L 36.9 (30.3–46.8) 39.2 (33.2–48.0) 27.9 (22.8–33.0) 0.001
PML betaine, mol/L 44.5 (34.1–53.9) 47.2 (40.1–58.3) 29.3 (27.0–38.8) 0.001
Choline, mol/L 9.0 (7.7–10.7) 9.4 (7.9–11.0) 8.0 (7.3–8.9) 0.008
PML choline, mol/L 10.3 (8.3–11.4) 10.4 (8.4–12.0) 9.6 (7.0–11.0) 0.02
DMG, mol/L 3.64 (3.17–4.58) 3.67 (3.27–4.63) 3.32 (2.79–4.10) 0.1
PML DMG, mol/L 4.54 (3.58–5.44) 4.58 (3.72–5.42) 4.17 (3.42–6.11) 0.4
Age, y 62 (54–68) 62 (55–68) 62 (53–70) 1.0
Creatinine, mol/L 94 (87–101) 96 (89–103) 80 (73–93) 0.001
Folate, nmol/L 8.2 (6.1–11.1) 7.8 (6.1–10.9) 8.8 (6.6–12.2) 0.4
Cobalamin, pmol/L 369 (311–481) 373 (319–437) 355 (297–425) 0.6
Vitamin B6‡, nmol/L 23.0 (17.7–37.1) 22.9 (15.7–37.0) 23.0 (18.3–39.7) 0.5
*Data are given as medians with interquartile ranges (25th–75th percentiles) in parentheses.
†Mann-Whitney U test.
‡Pyridoxal phosphate.
tHcy indicates total homocysteine; PML, postmethionine load; DMG, dimethylglycine.
TABLE 2. Spearman Correlations at Baseline
Age Creatinine PML tHcy Betaine PML betaine Choline DMG Folate Cobalamin Vitamin B6
tHcy 0.50† 0.44† 0.40† 0.07 0.07 0.18 0.32* 0.21* 0.21* 0.08
PML tHcy 0.14 0.08 0.23* 0.37† 0.01 0.03 0.06 0.13 0.02
Betaine 0.13 0.07 0.79† 0.49† 0.42† 0.06 0.02 0.05
PML betaine 0.15 0.18 0.34* 0.33* 0.08 0.11 0.00
Choline 0.17 0.28* 0.50† 0.05 0.12 0.19
DMG 0.28* 0.15 0.14 0.1 0.09
*P0.05.
†P0.001.
tHcy indicates total homocysteine; PML, postmethionine load increase; DMG, dimethylglycine.
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throughout the intervention period and showed a transient
increase after methionine loading (Figure 3).
We compared the basal and PML concentrations of be-
taine, choline, and DMG at 3 months according to the
treatment groups FB, F, B, and P. The metabolite concentra-
tions, except PML choline (P0.03), were not significantly
different between the groups (P0.4) (data not shown).
B-Vitamin Supplementation and the
Betaine–PML tHcy Relationship
After 3 months of intervention, plasma cobalamin and plasma
folate were higher than 277 pmol/L and 25 nmol/L, respec-
tively, in all patients in groups FB and F, and pyridoxal
phosphate was higher than 142 nmol/L in groups FB and B.
No significant changes in median levels of these vitamins
occurred in the nonsupplemented groups.
PML tHcy (mol/L; median [interquartile range]) de-
creased in the groups FB (from 19.4 [15.5 to 22.7] to 14.7
[11.6 to 17.2], P0.004), F (from 19.7 [16.6 to 24.6] to 15.8
[12.9 to 18.9], P0.002), and B (from 19.3 [15.3 to 23.6] to
16.3 [13.5 to 17.9], P0.005) given B-vitamins. PML tHcy
did not change in the placebo group P (from 20.9 [17.0 to
30.0] to 21.8 [16.3 to 30.2], P0.5).
After 3 months of intervention, the inverse association
between PML tHcy and PML betaine in the subjects
receiving B-vitamins was essentially abolished but was still
present in the subgroup (P) receiving placebo, as depicted in
Figure 2. Multiple linear regression analyses of the associa-
tion between PML tHcy and PML betaine in the separate
intervention groups demonstrated that the association was
absent in the groups FB and F administered folic acid
(P0.6), showed a trend in the group B administered vitamin
B6 (P0.09), and was still strong and significant in the group
P administered no B-vitamins (0.66, P0.02). All these
models were adjusted for age, sex, creatinine, cobalamin,
folate, and vitamin B6.
Predictors of PML tHcy at 3 months in the whole study
group were assessed by multiple regression (Table I, avail-
able online at http://atvb.ahajournals.org). The model con-
tained the B-vitamins, in addition to creatinine, age, and sex.
Figure 2. The relation between plasma betaine and the PML
increase in plasma tHcy at baseline and after 3 months of
B-vitamin supplementation. The upper panels show the relations
between betaine (basal and PML) and PML increase in plasma
tHcy before intervention. The lower left panel shows PML
betaine versus PML increase in tHcy in 22 subjects (group P)
administered placebo and the lower right panel shows this rela-
tionship in the remaining 68 subjects (groups FB, F, and B)
treated with B-vitamins. The curves were obtained by quadratic
regression, and the shaded areas represent the 95% confidence
interval of mean regression line.
TABLE 3. Determinants at Baseline of Basal Betaine, Choline,
Dimethylglycine, and the increase in tHcy After Methionine
Loading by Multiple Linear Regression*
Dependent Variable Independent Variables  P
Basal betaine Age 0.12 0.06
Sex 0.48 0.001
Creatinine 0.17 0.1
Folate 0.14 0.2
Cobalamin 0.09 0.4
Vitamin B6 0.005 0.9
Basal choline Age 0.08 0.4
Sex 0.12 0.2
Creatinine 0.37 0.001
Folate 0.11 0.3
Cobalamin 0.15 0.2
Vitamin B6 0.08 0.5
Basal DMG Age 0.16 0.2
Sex 0.07 0.5
Creatinine 0.24 0.04
Folate 0.08 0.5
Cobalamin 0.17 0.1
Vitamin B6 0.10 0.4
tHcy increase (Model I) Age 0.19 0.1
Sex 0.02 0.9
Creatinine 0.02 0.8
Folate 0.13 0.3
Cobalamin 0.06 0.6
Vitamin B6 0.08 0.5
Basal betaine 0.29 0.02
tHcy increase (Model II) Age 0.20 0.07
Sex 0.10 0.4
Creatinine 0.06 0.6
Folate 0.17 0.1
Cobalamin 0.09 0.4
Vitamin B6 0.02 0.9
PML betaine 0.47 0.001
*All variables are included in each of the models.
DMG indicates dimethylglycine; tHcy, total homocysteine.
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PML betaine was strongly associated with PML tHcy, but
the association was weaker (0.33, P0.007) than before
treatment (0.47, P0.001; Table 3). Plasma folate and,
to a lesser extent, vitamin B6 were also significant predictors.
Substitution of B-vitamin concentration with treatment
category in the regression model essentially did not change
the association between PML tHcy and PML betaine (data
not shown).
Discussion
We present data on the relation between betaine and plasma
tHcy in 90 patients with cardiovascular disease before and
during long-term intervention with folate, cobalamin, and
vitamin B6, as implemented in the WENBIT. We demon-
strate, for the first time to our knowledge, that the increase in
tHcy after methionine loading (PML tHcy) was determined
by PML betaine. Basal betaine was a weaker predictor. In 68
subjects supplemented with B-vitamins for 3 months, PML
tHcy was reduced, and its inverse relation to betaine was
weakened, particularly in the subgroups administered folic
acid.
Study Design
The strength of the study is its longitudinal, prospective
design, which allows comparison of betaine effects before
and after B-vitamin intervention in the same individuals. It
was clearly shown that in the combined group treated with
B-vitamins, the betaine-PML-tHcy association was essen-
tially abolished, but the small sample size provided limited
statistical power to delineate the effects of individual
B-vitamins.
We measured PML tHcy 4 hours after methionine inges-
tion. This short interval was chosen for logistic reasons. A
recent study demonstrated that at this time point, PML tHcy
has higher within-subject and between-subject coefficients of
variation (CV) than the PML tHcy measured at 6 or 8 hours
after methionine intake, possibly because of variable methi-
onine absorption a short time after loading.10 Furthermore, we
observed that betaine showed a stronger association with
PML tHcy than with PML tHcy. However, analytical CV
increases when PML tHcy is adjusted for basal tHcy to obtain
PML tHcy, because the variance has the property of being
additive.10 Thus, increased biological and analytical varia-
tions may actually lead to underestimation of the “true”
association between betaine status and PML tHcy.
Concentrations of Betaine, Choline,
and Dimethylglycine
The median plasma concentration of betaine reported here
(37 mol/L; Table 1) is similar to the concentration
previously reported by us in healthy blood donors22 and by
others.21,28 We observed a strong relation between betaine
and gender, with higher levels in males than in females (Table
1, Figure 3), which has also been reported by others.29 The
presence of consensus sites for steroid hormones, including
estrogen and androgen binding sites, in the human betaine
homocysteine methyltransferase gene30 may represent a mo-
lecular basis of sex steroid effects on plasma betaine.
We observed a median concentration of plasma choline
(9 mol/L) that is equal to the concentration (10 mol/L)
previously measured in healthy subjects22,31,32 The median
plasma DMG (3.6 mol/L) is somewhat higher than the
DMG levels (2 to 3 mol/L) previously reported by us and
others.22,28,33 Slightly elevated plasma DMG may be related
to the possibility that the cardiovascular patients have mod-
erately impaired renal function, which is known to affect the
DMG concentration.33 Conceivably, methodological differ-
ence may also account for different metabolite (DMG) levels
between various study populations.
Human Studies on Betaine and tHcy
The strong inverse association between PML tHcy and
plasma betaine, particularly PML betaine, in subjects not
receiving B-vitamin supplementation is the most important
result of the present study. The data are in agreement with
consistent observations that betaine supplementation reduces
PML tHcy and also fasting tHcy in healthy subjects16,18 and
tHcy in renal patients20 and in homocystinurics.34–36 How-
ever, our data (Table 2) do not confirm a recent observation
of a significant inverse relation between (basal) plasma
betaine and tHcy in 122 Canadian cardiovascular patients.21
Figure 3. Plasma concentration of choline, betaine, and dimeth-
ylglycine during B-vitamin supplementation and after methionine
loading. The metabolite concentrations are given separately for
men (filled circles) and women (open circles) according to time
after start of intervention. Arrows indicate methionine loading,
which was performed on day 0 and on day 84, and the values
obtained 4 hours after loading are included in the graph. Data
are given as medians and the shaded areas indicate the 25 to
75 percentiles.
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The apparent discrepancy may be related to different size,
B-vitamin status, or renal function of the two study popula-
tions. We are currently addressing the possible relation
between betaine and fasting tHcy in large population-based
studies.
Mechanisms and Role of Betaine in
Homocysteine Remethylation
Methionine loading caused a 3-fold increase in tHcy, a 15%
increase in plasma betaine and DMG, and also a significant
increase in choline (Table 1, Figure 3). The choline response
may reflect enhanced supply of choline for the synthesis of
betaine or a choline-sparing effect from superfluous methio-
nine. The elevation of plasma betaine and DMG levels,
however, indicates an increased flux through the BHMT
pathway, which is in accordance with the observation that
PML tHcy is strongly and inversely related to PML betaine
and also to PML increase in betaine. Thus, increased meta-
bolic flux through the choline-betaine-DMG pathway may
occur in response to high levels of homocysteine and/or
methionine.
After treatment with combinations of folic acid, vitamin
B12, and vitamin B6 for 3 months, the relation between PML
betaine and PML tHcy was weakened in the whole study
group and was abolished in the subgroups administered folic
acid. This indicates that enhancement of folate-dependent
remethylation catalyzed by methionine synthase downregu-
lates the BHMT reactions and suggests a cross-talk between
these two pathways.
The significance of betaine in homocysteine homeostasis is
not clear, but the view prevails that the BHMT mainly
functions to conserve homocysteine under conditions of
methionine deficiency.5 This assumption is based on animal
experiments demonstrating a dramatic induction of BHMT
during methionine deficiency in combination with excess
dietary choline.5,30,37–39
Our observation of an inverse relation between betaine and
PML tHcy indicates an additional function of the BHMT
pathway, ie, reduction of the homocysteine increase after
methionine intake. This idea is difficult to reconcile with the
fact that BHMT is inhibited by S-adenosylmethionine5 but
gains some support from experiments in rats, demonstrating a
moderate net increase in BHMT activity during methionine
excess.5 Suppression of high homocysteine under conditions
of excess methionine is thus obtained together with salvage of
homocysteine carbon backbone. This metabolic effect con-
trasts to the result of the vitamin B6-dependent cystathionine-
-synthase reaction, which irreversibly directs superfluous
homocysteine into the transsulfuration pathway.
Implications and Conclusion
The data presented here indicate that betaine through the
BHMT reaction buffers and tends to reduce homocysteine
during methionine excess. This reaction, which conserves the
homocysteine carbon backbone, may be beneficial under
conditions of limiting supply of folate required for enhance-
ment of the methionine synthase reaction. These findings
emphasize the complementary relationship between betaine
and folate metabolism and motivate population-based studies
on betaine status in pathologies related to folate deficiency
and homocysteine status.2 Furthermore, because PML tHcy
confers increased risk for occlusive vascular disease indepen-
dent of fasting tHcy,11 betaine and related metabolites should
be included in future studies of homocysteine and cardiovas-
cular risk. Because basal betaine showed a significant relation
to PML tHcy as well, the role of betaine could be investi-
gated in epidemiological studies based on biobanks, where
PML samples may not be available.
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Abstract. Bleie Ø, Semb AG, Grundt H, Nordrehaug
JE, Vollset SE, Ueland PM, Nilsen DWT, Bakken
AM, Refsum H, Nyga˚rd OK (Haukeland University
Hospital, Bergen; University of Bergen, Bergen;
Diakonhjemmet Hospital, Oslo; Stavanger University
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lowering therapy does not affect inﬂammatory
markers of atherosclerosis in patients with stable
coronary artery disease. J Intern Med 2007;
262: 244–253.
Objectives. A high level of total homocysteine (tHcy)
is a risk marker for cardiovascular disease (CVD),
and is related to inﬂammation. We wanted to test the
effect of homocysteine-lowering B-vitamin therapy, as
used in the Western Norway B-vitamin Intervention
Trial (WENBIT), on inﬂammatory markers associated
with atherosclerosis.
Design. Single centre, prospective double-blind clinical
interventional study, randomised in a 2 · 2 factorial
design.
Subjects and methods. Ninety patients (21 female) with
suspected coronary artery disease (CAD), aged 38–
80 years, were blindly randomised into one of four
groups of daily oral treatment with (A) folic acid
(0.8 mg)/vitamin B12 (0.4 mg)/vitamin B6 (40 mg),
(B) folic acid/vitamin B12, (C) vitamin B6 alone or
(D) placebo. Blood samples were collected before and
after 6 months of treatment.
Results. Before intervention, median levels of the ana-
lytes were: tHcy 11.0 lmol L)1, neopterin
8.1 nmol L)1, soluble CD40 ligand (sCD40L)
3.9 ng mL)1, interleukin (IL)-6 1.9 pg mL)1, C-react-
ive protein (CRP) 1.9 mg L)1 and low-density lipo-
protein (LDL) cholesterol 3.3 mmol L)1. tHcy was
signiﬁcantly associated with neopterin (r ¼ 0.49,
P < 0.001) and with IL-6 (r ¼ 0.29, P ¼ 0.01),
but not with CRP or sCD40L. Neither treatment with
folic acid/B12 nor with B6 induced signiﬁcant chan-
ges in any of these inﬂammatory biomarkers
(P ‡ 0.14). In patients receiving folic acid/B12
(groups A and B), tHcy was reduced with 33%
(P < 0.001).
Conclusions. In patients with stable CAD, homocyste-
ine-lowering therapy with B-vitamins does not affect
levels of inﬂammatory markers associated with ather-
ogenesis. Failure to reverse inﬂammatory processes,
may partly explain the negative results in clinical
secondary B-vitamin intervention trials.
Keywords: atherosclerosis, B-vitamins, homocysteine,
inﬂammation, neopterin, soluble CD40 ligand.
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Introduction
Numerous studies demonstrate that hyperhomocystein-
aemia is related to an increased risk of the existence,
extent and progression and of prognosis of cardiovascular
disease (CVD) [1, 2]. Recent data also indicate that
homocysteine is associated with several important
components of atherogenesis, including endothelial
dysfunction, platelet and immune activation and
inﬂammation [3–5].
Based on these observations, several randomised clin-
ical trials with homocysteine-lowering B-vitamins
have been initiated in order to investigate whether
homocysteine is causally related to atherosclerosis [6].
In published trials, no signiﬁcant effect on the primary
outcome was documented in patients with stroke
(VISP) [7], acute myocardial infarction (NORVIT)
[8], CVD (HOPE-2) [9] or chronic renal failure
(ASFAST) [10]. A nearly signiﬁcant increase of myo-
cardial infarction was demonstrated in the NORVIT
trial (in the group receiving both folic acid and vita-
min B6) [8], whereas a signiﬁcant reduction in stroke
was demonstrated in HOPE-2 [9]. Both the VISP and
the ASFAST trials were underpowered to detect clin-
ical effects of the intervention of a magnitude similar
to what might have been expected from the epidemio-
logical data [7, 10]. In addition, two randomized trials
evaluating restenosis after PCI showed conﬂicting
results [11, 12]. Thus, the results from these clinical
trials still leave uncertainty of the possible role of
homocysteine in the progression of atherosclerotic dis-
ease. It is therefore important to investigate the meta-
bolic effects of B-vitamin supplementation to
understand why intervention may fail despite of epi-
demiological evidence.
Inﬂammation and persistent immune activation are hall-
marks of the atherosclerotic process [13]. The markers
C-reactive protein (CRP), CD40 ligand (CD40L) and
neopterin represent different inﬂammatory pathways
related to atherogenesis. CRP is an acute phase reac-
tant; the production of CRP is stimulated by interleukin
(IL)-6 effects on the liver. CRP represents an overall
marker of the inﬂammation and is extensively investi-
gated and characterized [14]. CD40L is produced by
many cell types, but is excreted mainly from platelets
and is related to unstable coronary artery disease
(CAD) [15]. Soluble CD40L (sCD40L) may therefore
reﬂect the role of activated platelets in inﬂammation
[16]. Neopterin is a pteridine which reﬂects activation
of the cellular part of inﬂammation, and is released
from activated monocytes through stimulation by inter-
feron (IFN)-c from T lymphocytes [17]. Neopterin has
been related to the extent [18], complexity [19] and
progression [20] of the atherosclerotic disease. Further-
more, neopterin is strongly related to the homocysteine
homeostasis [21].
The current investigation was designed to assess the
effects of homocysteine-lowering B-vitamins on
inﬂammatory markers associated with atherosclerosis.
The investigation is a substudy of the Western Nor-
way B-vitamin Intervention Trial (WENBIT), a rand-
omised placebo-controlled clinical trial in patients
with CAD.
Subjects and methods
Patients, recruitment and study design
Western Norway B-vitamin Intervention Trial is a
prospective randomised double-blind study on the
clinical effects of homocysteine-lowering therapy in
3098 adult patients undergoing coronary angiography
for suspected CAD. Using a 2 · 2 factorial design,
we could simultaneously assess the effect of the com-
bination of folic acid/vitamin B12 versus no folic
acid/vitamin B12 and separately vitamin B6 versus no
vitamin B6. Patients were accordingly randomised
into four groups – Group A: folic acid (0.8 mg), vita-
min B12 (cyanocobalamin 0.4 mg) and vitamin B6
(pyridoxine 40 mg); Group B: folic acid and vitamin
B12; Group C: vitamin B6 or Group D: placebo. For
the ﬁrst 2 weeks, Group A and Group B received an
additional loading dose of folic acid (5 mg day)1).
Packages of trial capsules were prepared and random-
ised in blocks of 20 by Alpharma A/S (Copenhagen,
Denmark).
The current study is conﬁned to a subgroup of 90
consecutive patients who were recruited at start of
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the WENBIT study, in the period of April 1999 to
September 1999. These patients underwent more
extensive follow up during the initial 6 months of the
intervention, a follow up designed to investigate mech-
anisms and biochemical effects of provided treatment.
One patient died, two patients withdrew their consent.
A total of 83 patients attended the visit at 6 months.
This subpopulation of WENBIT has been character-
ized in detail previously [22]. The study protocol was
approved by the Regional ethics committee and by the
Norwegian Medicines Agency. Written informed con-
sent was obtained from all patients.
Blood collection and biochemical analyses
In the present study, we used nonfasting blood sam-
ples collected at baseline and after 6 months of
B-vitamin intervention. EDTA blood samples for
analysis of B-vitamins, total homocysteine (tHcy) and
metabolites were immediately placed on ice and
centrifuged within 30 min. Plasma and serum were
stored at )80 C until further analysis.
Routine blood analyses, including haematological
parameters, renal function markers and lipid-related
factors, were analysed at Laboratory of Clinical
Biochemistry, Haukeland University Hospital, using
Technicon Chem 1 (Bayer, Leverkusen, Germany)
and CELL-DYN 4000 (Abbot, Abbott Park, IL,
USA) platforms. tHcy and MMA were analysed using
a modiﬁcation of a gas chromatography method based
on ethylchloroformate derivatization [23]. Plasma
folate [24] and cobalamin [25] were analysed by pub-
lished methods. Results on vitamin B6 (pyridoxal
phosphate, PLP) have previously been presented [26].
Commercially available enzyme immunoassays were
used to determine serum levels of sCD40L [intra-
assay coefﬁcient of variation (CV) 6.8%; Bender
Medsystems, Vienna, Austria] and serum neopterin
(CV 3.6–6.8%; IBL, Hamburg, Germany). Analyses
were performed according to the manufacturer’s
instructions and in duplicates on the same microtitre
plate. IL-6 was analysed in duplicates by ELISA tech-
nique (CV 6.9–7.8%; R&D Systems, Abingdon, UK).
CRP was determined in serum by an ultra sensitive
immunoassay applying the Behring nephelometer II
system (CV 8.1–11.4%; N Latex CRP mono, Behring
Diagnostics, Germany).
Glomerular ﬁltration rate (GFR) was calculated
according to the 4-variable Modiﬁcation of Diet in
Renal Disease Equation [27], estimating GFR from
creatinine, age, gender and ethnicity.
Statistical analysis
Because of the skewed distribution of vitamins and
metabolites, continuous variables are reported as
medians with interquartile range or geometric mean
with reference range. Categorical variables are presen-
ted as numbers and proportions. Associations were
assessed by Spearman rank correlation and linear
regression. Kruskal–Wallis test was used for compar-
ison of continuous variables between treatment
groups. Wilcoxon signed rank test was used for com-
parison within groups over time. Effect of folic acid/
B12 or vitamin B6 over time was also studied by
repeated-measures anova according to the 2 · 2
study design, using log-transformed numbers. Power
calculations by PASS 2005 (NCSS, Kaysville, UT,
USA) and nquery advisor 6.0 (Statistical Solutions,
Cork, Ireland) were based on a sample volume of 90
patients, a loss to follow up <10% and a signiﬁcance
level of 0.05. We calculated a power of 95% to detect
a change of 20% in neopterin level by treatment
(patients divided into two groups; folate and non
folate or vitamin B6 and non-B6) using Wilcoxon
signed rank test. In the univariate two-group repeated
measure analysis, a power of 99% to detect a change
in neopterin level of 20% by treatment during
6 months was calculated. Data were analysed using
spss 13.0 (SPSS Inc., Chicago, IL, USA).
Results
Subject characteristics at baseline
A total of 90 patients, all Caucasian, 21 female and
69 male, with median age 62 years (range: 38–80)
were included. Major characteristics of the patients
are given in Table 1. Except for tHcy (P ¼ 0.05),
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no signiﬁcant differences for these variables were
found between the four groups. Additional demogra-
phic data, including smoking, diabetes, prior myocar-
dial infarction, prior revascularization, body mass
index, blood pressure, details about cholesterol, creati-
nine and vitamin indices, have been presented earlier
[22].
Median levels (25–75th percentiles) of key biomark-
ers was: tHcy 11.0 (9.3–12.9) lmol L)1, neopterin
8.1 (5.4–10.6) nmol L)1, sCD40L 3.9 (2.3–5.6)
ng mL)1, IL-6 1.9 (1.1–3.2) pg mL)1, CRP 1.9 (0.9–
3.7) mg L)1 and LDL cholesterol 3.3 (2.7–4.0)
mmol L)1. Baseline levels of inﬂammatory markers,
except for IL-6, did not differ signiﬁcantly between
treatment groups (Table 2).
Association between tHcy or vitamins and inflammatory
biomarkers at baseline
The univariate association between tHcy or vitamins
and biomarkers at baseline are shown in Table 3. In
addition to its well-known relations with age, creati-
nine, folate and cobalamin, baseline tHcy was posi-
tively associated with IL-6, and neopterin. No
association was found between tHcy and LDL choles-
terol. Amongst the B-vitamins, plasma folate was not
associated with any of the biomarkers. Plasma cobal-
amin was positively related with sCD40L, whereas
vitamin B6 (PLP) showed an inverse relation with IL-
6. As expected, we observed signiﬁcant associations
between the different inﬂammatory markers. Both
tHcy and neopterin were signiﬁcantly associated with
creatinine, age and gender. After adjustment for GFR,
tHcy was still signiﬁcantly correlated with neopterin
(r ¼ 0.38, P < 0.001), but not IL-6 (r ¼ 0.13,
P ¼ 0.23).
In order to evaluate the association, we carried out
multiple linear regression analyses with each of the
various inﬂammatory markers as dependent variables,
and tHcy, GFR, LDL cholesterol, folate, vitamin B6
and vitamin B12 as independent variables (all inde-
pendent variables in each of the analyses). Predictors
of neopterin were levels of tHcy (b ¼ 0.35,
P < 0.001), GFR (b ¼ )0.37, P < 0.001) and LDL
cholesterol (b ¼ 0.34, P < 0.001). sCD40L was
borderline associated with GFR (b ¼ 0.25, P ¼
0.05). No such associations with CRP or IL-6 were
found in this model.
Table 1 Characteristics of the study population at baseline
Total groupa
(n ¼ 90)
Treatment groupsa
P-valueb
Folic acid/B12/B6
(n ¼ 22)
Folic
acid/B12
(n ¼ 23)
B6
(n ¼ 21)
Placebo
(n ¼ 24)
Age (years) 62 (54–68) 64 (55–70) 59 (52–65) 61 (57–71) 64 (53–71) 0.4
Women, n (%) 21 (23) 6 (27) 3 (13) 7 (33) 5 (21) 0.4
Creatinine (lmol L)1) 94 (87–101) 91 (83–98) 94 (89–101) 90 (82–98) 98 (91–114) 0.07
GFR (mL min/1.73 m2) 73 (64–79) 75 (65–82) 73 (67–80) 72 (64–80) 74 (58–76) 0.5
Total cholesterol (mmol L)1) 5.3 (4.8–6.1) 5.5 (4.7–6.2) 5.3 (4.9–5.7) 5.4 (4.8–6.4) 5.2 (4.2–7.0) 0.9
LDL cholesterol (mmol L)1) 3.3 (2.7–4.0) 3.6 (2.7–4.0) 3.3 (2.8–3.9) 3.4 (2.4–4.4) 3.3 (2.3–4.8) 0.9
Statin use, n (%) 65 (72) 14 (64) 20 (87) 13 (62) 18 (75) 0.2
tHcy (lmol L)1) 11.0 (9.3–12.9) 9.9 (9.0–11.9) 12.0 (10.3–13.1) 11.3 (8.8–12.1) 11.4 (9.9–15.8) 0.05
Plasma folate (nmol L)1) 8.2 (6.1–11.1) 8.3 (6.1–10.9) 7.7 (5.6–11.3) 8.2 (6.6–10.7) 9.0 (5.8–11.8) 0.9
Cobalamin (pmol L)1) 369 (311–431) 361 (321–402) 400 (316–469) 361 (313–463) 349 (270–400) 0.2
Vitamin B6 (PLP, nmol L)1) 23.0 (17.7–37.1) 21.5 (16.5–33.5) 27.9 (19.3–44.6) 21.8 (15.0–39.7) 24.3 (16.1–39.5) 0.6
aData are presented as median (25–75th percentiles) or numbers (%).
bKruskal–Wallis test between treatment groups.
GFR, estimated glomerular ﬁltration rate; LDL, low-density lipoprotein; B6, vitamin B6; PLP, pyridoxal 5-phosphate.
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Effect of treatment
Combination of folic acid and vitamin B12 caused a
signiﬁcant increase in plasma folate and plasma cobal-
amin, and a 33% reduction in plasma tHcy (from
median 11.0 lmol L)1 to median 7.4 lmol L)1,
P < 0.001; Fig. 1). Neither folic acid/vitamin B12 nor
vitamin B6 signiﬁcantly inﬂuenced the levels of the
inﬂammatory markers (Table 2 and Fig. 1). Analysing
the effect of folic acid/B12 (combined Groups A + B)
Table 2 Values of inﬂammatory markers at baseline and after 6 months
Total group
Treatment groups
P-valueaFolic acid/B12/B6 (A) Folic acid/B12 (B) B6 (C) Placebo (D)
Neopterin (nmol L)1)
n 83 22 21 19 21
Baseline 7.6 (7.0–8.2) 7.1 (6.1–8.2) 7.9 (6.8–9.3) 6.8 (5.8–8.0) 8.6 (7.1–10.4) ns
6 months 7.7 (7.1–8.3) 8.1 (7.0–9.3) 7.3 (6.2–8.6) 7.0 (6.2–8.0) 8.3 (6.8–10.1) ns
P-valueb ns ns ns ns ns
sCD40L (ng mL)1)
n 81 22 21 19 19
Baseline 3.6 (3.1–4.1) 3.9 (2.9–5.3) 3.8 (3.0–4.8) 3.5 (2.5–5.0) 3.1 (2.5–3.9) ns
6 months 3.2 (2.6–4.0) 3.3 (2.1–5.2) 3.6 (2.5–5.3) 3.7 (2.4–5.7) 2.4 (1.4–4.0) ns
P-valueb ns ns ns ns ns
IL-6 (pg mL)1)
n 83 22 21 19 21
Baseline 1.8 (1.5–2.1) 1.5 (1.0–2.0) 1.5 (1.1–2.1) 2.8 (2.1–3.8) 1.8 (1.4–2.5) 0.02
6 months 1.7 (1.5–1.9) 1.6 (1.2–2.2) 1.4 (1.1–1.7) 2.0 (1.5–2.6) 1.8 (1.4–2.3) ns
P-valueb ns ns ns ns ns
CRP (mg L)1)
n 83 22 21 19 21
Baseline 1.8 (1.4–2.3) 1.5 (1.0–2.2) 1.9 (1.3–2.8) 2.4 (1.4–4.1) 1.5 (0.8–2.8) ns
6 months 1.9 (1.5–2.5) 1.5 (1.0–2.2) 2.4 (1.5–3.8) 2.0 (1.2–3.3) 1.9 (1.0–3.6) ns
P-valueb ns ns ns ns ns
aKruskal–Wallis test between treatment groups.
bWilcoxon signed rank test between baseline and 6 months. Data are presented as geometric mean in natural units and geometric reference
range in parentheses (antilog: mean log ± 1.96 SEM).
B12, vitamin B12; B6, vitamin B6; sCD40L, soluble CD40 ligand; IL-6, interleukin 6; CRP, C-reactive protein.
Table 3 Spearman correlations at baseline
Age Creatinine GFR LDL-chol Neopterin sCD40L IL-6 CRP Folate Cobalamin Vitamin 6
tHcy 0.50 0.44 )0.34 )0.09 0.49 )0.10 0.29 0.16 )0.21* )0.21* )0.02
LDL-chol )0.13 0.00 )0.03 0.11 0.01 )0.10 0.01 )0.04 0.08 0.09
Neopterin 0.36 0.41 )0.45 0.08 0.30 0.23* )0.09 0.07 )0.05
sCD40L )0.09 )0.15 0.20 0.07 0.01 0.03 0.29 0.05
IL-6 0.32 0.07 )0.13 0.41 )0.09 )0.13 )0.24*
CRP 0.11 0.05 )0.01 )0.09 )0.07 )0.05
*P < 0.05;  P < 0.01.
GFR, estimated glomerular ﬁltration rate; LDL-chol, low-density lipoprotein cholesterol; sCD40L, soluble CD40 ligand; IL-6, interleukin 6;
CRP, C-reactive protein; tHcy, total homocysteine.
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between baseline and 6 months, reveal no signiﬁcant
effect on neopterin (P ¼ 0.78), sCD40L (P ¼
0.67), IL-6 (P ¼ 0.96) or on CRP (P ¼ 0.83).
Testing the effect of vitamin B6 (A + C), show a
similar negative result; neopterin (P ¼ 0.25),
sCD40L (P ¼ 0.45), IL-6 (P ¼ 0.50) and CRP
(P ¼ 0.33). Tested by repeated measures anova, no
effect of folic acid/B12 (Groups A + B versus C + D)
was observed on neopterin (P ¼ 0.76), sCD40L
(P ¼ 0.99), IL-6 (P ¼ 0.34) or on CRP
(P ¼ 0.83). Likewise, no effect of vitamin B6
(Groups A + C versus B + D) was observed on neop-
terin (P ¼ 0.07), sCD40L (P ¼ 0.77), IL-6
(P ¼ 0.79) or on CRP (P ¼ 0.22).
The strong relation seen at baseline between tHcy and
neopterin in multiple linear regression analyses, was
relatively unchanged after 6 months in those subjects
receiving vitamin B6 alone or placebo (b ¼ 0.43,
P ¼ 0.003). In patients receiving folic acid and vita-
min B12, this relation was no longer present
(b ¼ )0.05, P ¼ 0.8).
During the observation period, 19 patients started or
intensiﬁed statin therapy (ﬁve patients in Group A,
ﬁve in Group B, four in Group C and ﬁve in Group
D) and two patients reduced the statin dose (in Groups
C and D). Mean increase in statin dose was equally
distributed between Groups A–D (2.8, 2.7, 2.5 and
3.3 mg, respectively). As a result, median LDL choles-
terol was reduced by 0.4 mmol L)1 (P ¼ 0.001)
without signiﬁcant difference in LDL cholesterol
between treatment groups (P > 0.9). In a multiple lin-
ear regression model adjusting for tHcy, GFR, folate,
vitamin B6 and vitamin B12, inﬂammatory markers
neopterin, sCD40L, IL-6 or CRP at 6 months were not
associated with level of LDL cholesterol (P ‡ 0.1) or
change in LDL cholesterol (P > 0.3).
Discussion
In the current substudy of WENBIT, we evaluated the
effect of B-vitamin intervention on important bio-
markers of atherogenesis. Prior investigations have
not only indicated that tHcy is signiﬁcantly related to
many of these processes [5, 28], but also indicate that
folate and vitamin B6 are associated with CVD, inde-
pendent from their relation with tHcy [29]. However,
despite the fact that plasma tHcy was lowered by
33% by folate 0.8 mg combined with vitamin B12
0.4 mg, and that a high dose of vitamin B6 (40 mg)
Fig. 1 Cumulative frequency plots of change in concentra-
tion between baseline and 6 months of plasma total homo-
cysteine (tHcy; n ¼ 83; upper panel), serum neopterin
(n ¼ 83; middle panel) and serum soluble CD40 ligand
(sCD40L; n ¼ 81; bottom panel), presented in four treat-
ment groups.
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was given, no signiﬁcant changes in the evaluated
biomarkers neopterin, sCD40L, IL-6 or CRP were
observed.
Statins is known to have immunomodulatory effects
[16], and 72% of patients were on statin therapy at
baseline (Table 1). Statin therapy was intensiﬁed dur-
ing the study period, but no differences were observed
in LDL cholesterol between groups at follow up. In
theory, change in statin therapy and change in level
of cholesterol may interfere with the inﬂammatory
markers and even mask an effect of B-vitamin therapy
on inﬂammation. This is, however unlikely, because
the LDL reduction was modest and uniform between
groups. Moreover, LDL cholesterol at 6 months was
not associated with any of the inﬂammatory markers.
Because a moderate dose of folic acid was provided,
we may not exclude that higher doses might have pro-
voked different effects. However, folic acid/vitamin
B12 therapy was associated with a marked 33% reduc-
tion in tHcy after 6 months. A similar reduction (27%)
was found in NORVIT applying an identical regimen
[8]. Despite higher doses of folic acid, less tHcy reduc-
tions (18–19%) were achieved in other clinical trials.
This may partly be due to voluntary intake of B-vitamin
supplements [10] or mandatory [7, 9] folate fortiﬁcation
programmes. It is noteworthy that our study is
performed in a nonfortiﬁed population.
Our observation of a particular strong relation
between tHcy and the marker of cellular immune
response, neopterin, corroborates results from several
previous reports [30, 31]. Neopterin is produced by
activated macrophages and dendritic cells in response
to stimulation by IFN-c released from T lymphocytes,
which are present at all stages of atherogenesis [17].
IFN-c also inhibits collagen synthesis in vascular
smooth muscle cells and increases collagen degrada-
tion by stimulating release of metalloproteinases from
macrophages [13]. Elevated levels of neopterin
(8.8 nmol L)1 compared with 6.9 nmol L)1) [20]
have been related to atherosclerotic progression and
clinical events, possibly reﬂecting plaque destabiliza-
tion associated with cell-mediated (Th1) immune
response [5].
It has been suggested that stimulation and prolifer-
ation of immune cells may facilitate the production of
reactive oxygen species (ROS), which may increase
the demand of B-vitamins [5]. Although this was sup-
ported by the observation of a signiﬁcant association
between folate status and neopterin in patients with
vascular disease [32], folate therapy caused only a
minor and nonsigniﬁcant reduction of neopterin in the
same study [32]. Stimulated human peripheral blood
mononuclear cells (PBMCs) may respond with a par-
allel increase in both neopterin and homocysteine pro-
duction, indicating that an increased homocysteine
level is a direct cause of the Th1 immune response
[5].
The most important ﬁnding from our study is the lack
of effect of B-vitamins on the inﬂammatory markers,
including neopterin, measured at follow up, indicating
that vitamin B treatment may not reverse cellular-
mediated inﬂammation involved in atherosclerosis.
This is supported by observations on neopterin after
B-vitamin treatment in demented patients [33]. More-
over, we found the association between neopterin and
homocysteine at baseline was only modestly attenu-
ated when we controlled for GFR, indicating mecha-
nisms for elevated levels of both neopterin and
homocysteine independent of renal function. In
patients treated with folic acid/vitamin B12, there
were no longer an association between homocysteine
and neopterin. This suggests that an optimal folate
status override the inﬂuence of immunostimulation
on tHcy plasma levels. Our data further indicate that
the utility of homocysteine as a predictor of CVD is
limited to subjects not taking folic acid/vitamin B12
supplement.
CD40 ligand is structurally related to tumour necrosis
factor (TNF)-a, and the activity of the TNF-a system
has recently been shown to be signiﬁcantly associated
with homocysteine concentration [15, 34]. Both trans-
membrane bound and soluble CD40L, predominantly
released from activated platelets, may interact with
CD40 resulting in various immunomodulatory or
inﬂammatory responses involved in arthrosclerosis
development, progression and plaque destabilization
[15, 16]. We found no association between tHcy and
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sCD40L in this study, and treatment with B-vitamins
did not signiﬁcantly inﬂuence concentrations of
sCD40L. Similar results have been observed in
patients with cerebrovascular disease [35], although
these patients had lower levels of sCD40L compared
with our patients (sCD40L 0.55 ng mL)1 vs.
3.9 ng mL)1, respectively). Thus, tHcy or B-vitamins
may not be an important determinants of platelet
activation in CAD patients treated with established
medical therapy.
Previous investigations have shown that increasing
levels of homocysteine in cell cultures may affect
monocytes [36] and endothelial cells [37] to pro-
mote IL-6 production. IL-6 is the principal procoag-
ulant cytokine, stimulating increased blood levels of
ﬁbrinogen, plasminogen activator inhibitor type 1
and CRP [38], and may promote the atherogenesis
[13]. A signiﬁcant association between tHcy and
IL-6 has previously been reported in elderly with
diabetes [39], but not in patients with CAD or per-
ipheral artery disease [30]. We found that IL-6 was
signiﬁcantly related to tHcy at baseline, but CRP
was not related to tHcy or the B-vitamins. IL-6 and
CRP were both unaffected by the B-vitamin treat-
ment, in line with previous results in patients with
cerebrovascular disease [35]. Our population had
relatively low baseline levels of CRP, possibly
reﬂecting that this cohort comprised medically well
treated patients with stable CAD.
Conclusions
Elevation of plasma tHcy is related to cardiovascular
events and linked to inﬂammation in CVD patients
not supplemented with B-vitamins. Secondary tHcy-
lowering B-vitamin intervention trials have so far
demonstrated no signiﬁcant reduction CVD events
[40]. Our study demonstrated that treatment with
folic acid/vitamin B12 or vitamin B6 had no
detectable effects on levels of neopterin, sCD40L, IL-
6 or CRP. Failure to reverse inﬂammatory processes
associated with atherosclerosis may partly explain the
negative results of B-vitamin intervention in patients
with established CVD treated with conventional
therapy.
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 1
Coronary vascular function and folic acid therapy 
Abstract 
 
Purpose. We examined the effects of B-vitamin therapy on coronary flow and vascular 
function in patients with established coronary artery disease (CAD). 
Methods and results. Forty patients with CAD and on statin treatment, recruited into the 
Western Norway B-Vitamin Intervention Trial (WENBIT), were randomly assigned to daily 
oral treatment with 0.8 mg folic acid and 0.4 mg vitamin B12 or placebo, and 40 mg vitamin 
B6 or placebo, using a 2 x 2 factorial design. At baseline, and after 9 and 24 months, coronary 
blood flow were assessed by coronary angiography and doppler flow-wire measurements 
during intra-coronary infusion of saline (basal), incremental (0.72 µg/min, 7.2 µg/min and 
36.0 µg/min) doses of acetylcholine, 2.4 mg/min adenosine and nitroglycerin. 
At baseline, mean (SD) age was 57.8 (9.0) years (eight females), serum LDL-cholesterol 2.9 
(0.7) mmol/L, creatinine 88 (9.9) µmol/L, folate 12.2 (6.5) nmol/L and plasma total 
homocysteine 10.7 (2.9) µmol/L (p≥0.4 between treatment groups). We found a significant 
increase in basal (p<0.02) and adenosine-induced (p<0.05) coronary blood flow in subjects 
who received folic acid/vitamin B12 compared to placebo or vitamin B6 alone for 24 months. 
Folic acid/vitamin B12 or vitamin B6 treatment did not change endothelial-dependent 
response following acetylcholine infusion or flow-dependent proximal dilatation in response 
to adenosine-induced maximal hyperemia (p≥0.45). 
Conclusion. Treatment with a combination of folic acid and vitamin B12 increased basal and 
adenosine-induced maximal coronary blood flow, reflecting improved vascular function. The 
potential beneficial effect of folic acid therapy on vascular function should be furthered 
studied. 
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INTRODUCTION 
Numerous studies suggest that the serum or plasma concentration of total homocysteine 
(tHcy) is an independent risk factor for cardiovascular disease (CVD) 1,2. The mechanisms of 
this association are not fully understood 3,4. To date, randomized trials on secondary 
prevention of CVD have shown no benefit on risk of cardiac events or mortality by 
homocysteine-lowering folic acid supplementation 5. Still, high levels of tHcy is associated 
with arterial endothelial dysfunction 6 and even postprandial increments in tHcy are found to 
impair endothelial function 7. 
Intact endothelium is important for the maintenance of vascular integrity and regulates 
vasomotor tone through release of nitric oxide to meet increased blood flow demands during 
physical strain. Endothelial dysfunction is an early marker of atherosclerotic disease, it is 
involved in the pathogenesis, and is associated with future cardiac events 8,9. Various 
treatment strategies have been shown to improve endothelial function and cardiovascular 
prognosis, including statins, angiotensin converting enzyme inhibitors and exercise 8. 
High doses of folic acid given to patients with CVD improve endothelial function 
measured as flow-mediated dilatation (FMD) in forearm arteries in some, but not in all studies 
10. However, low dose (0.4 mg/d) folate therapy seems to be ineffective 11,12. Typically, the 
duration of the studies was for a few weeks to months 10. 
So far, only one study has evaluated the effect of folic acid and vitamin B12 on 
coronary endothelial function in patients with coronary artery disease (CAD) 13, and no study 
investigated vitamin B6 alone. The objective of this substudy of the Western Norway B-
vitamin Intervention Trial (WENBIT) was to evaluate the long-term effect of homocysteine-
lowering B-vitamin therapy on coronary vascular function. The study population was patients 
with established stable CAD receiving contemporary medical therapy, including statins, and 
with no selection according to tHcy levels at baseline. 
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SUBJECTS AND METHODS 
 
Patients, recruitment and study design 
The current study is a single center substudy of WENBIT, a prospective randomized double-
blind study on the clinical effects of homocysteine-lowering therapy in 3090 adult patients 
undergoing coronary angiography for suspected CAD. Recruitment to WENBIT was started 
in 1999 and completed in March 2004. Using a 2 x 2 factorial design, we could 
simultaneously assess the effect of the combination of folic acid/vitamin B12 versus no folic 
acid/vitamin B12 and separately vitamin B6 versus no vitamin B6. Patients were randomized 
into four groups: Group A, folic acid (0.8 mg), vitamin B12 (cyanocobalamin 0.4 mg) and 
vitamin B6 (pyridoxine 40 mg); group B, folic acid and vitamin B12; group C, vitamin B6; 
group D, placebo. For the first two weeks, group A and group B received an additional 
loading dose of folic acid (5 mg/day). Packages of trial capsules were prepared and 
randomized in blocks of 20 by Alpharma A/S (Copenhagen, Denmark). 
In this substudy of coronary vascular function, patients with stable CAD scheduled for 
elective percutaneous coronary intervention were eligible. Exclusion criteria were malignant 
disease, alcohol abuse, mental illness, reluctance or incapability to long-term follow-up. Other 
exclusion criteria were predicted high risk for procedural complications, severe chronic 
obstructive pulmonary disease, pulmonary hypertension, significant valvular disease, 
glaucoma, poorly regulated diabetes, or use of systemic corticosteroids. Furthermore, blood 
pressure should be well regulated and there should be no indication for starting angiotensin 
converting enzyme inhibitor or calcium blocker therapy at the time of inclusion. All patients 
were treated with statins for at least two months prior to inclusion. Long-acting nitrates were 
not allowed the last week before the testing procedures. 
After successful treatment of at least one significant coronary stenosis, a non-
intervened coronary artery (belonging to the left anterior descending artery or circumflex 
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artery) was used for baseline coronary function testing (study vessel). Forty patients were 
followed with repeated testing after nine months, and 35 patients returned for a third testing 
after two years of vitamin treatment. Four patients did not wish to follow the two year per 
protocol catheterization, and in one patient, the vascular function testing was not successfully 
performed at the two year visit due to technical problems. No procedure related complications 
occurred. 
The study protocol was approved by the Regional ethics committee, and the 
medication was approved by the Norwegian Medicines Agency. Written informed consent 
was obtained from all patients. 
 
Assessment of coronary vascular function 
Measurements were done during consecutive intracoronary administration of saline, 
acetylcholine, adenosine and nitroglycerin. Acetylcholine induces a vasodilatation mediated 
by release of nitric oxide (NO) from intact endothelium, counterbalancing its direct effect on 
smooth muscles in the vessel wall causing vasoconstriction. The response to acetylcholine 
infusion thereby reflects endothelial function 14. Adenosine provokes hyperemia mainly by 
stimulating endothelium-independent dilatation in the microcirculation 15 and was used for 
assessment of maximum hyperemic flow in coronary arteries. Intracoronary nitroglycerin is a 
direct precursor of NO, and was used to measure endothelial-independent function. 
 
Procedures 
All patients were given heparin at start of the procedure to obtain an activated clotting time of 
300 s. Guiding catheters 6-French (Launcher, Medtronic, Minnespolis, MN) were used for 
cannulation of the left main coronary artery. Before vascular function testing, intracoronary 
nitrates were not permitted. A doppler guide wire (0.014 inch, FloWire, Volcano, Rancho 
 5
Coronary vascular function and folic acid therapy 
Cordova, CA) was placed in a non-branching segment of the study vessel through the inner 
lumen of a 2.9-French coronary infusion catheter (UltraFuse-X, Boston Scientific, Maple 
Grove, MN) ending 1 cm distal to the catheter tip. The positions of the infusion catheter and 
doppler wire were documented by angiography. Infusion through the UltraFuse-X catheter 
was done at 60 mL/hour (1 mL/min) with a pump delivering high-pressure output (Asena, 
Alaris, Basingstoke, UK). Infusions were done as follows in seven steps: 1) Saline 0.9% for 
three minutes, 2-4) incremental dosage (0.72 µg/min, 7.2 µg/min and 36.0 µg/min) of 
acetylcholine (Miochol-E 10 mg/mL, Novartis Healthcare, Copenhagen, Denmark) for three 
minutes and 20 seconds each (estimated transit time of 20 seconds), 5) saline 0.9% for 
approximately five minutes until return to basal flow (see below), 6) adenosine (Adenocor, 
Sanofi-Synthelabo, Bromma, Sweden) at a dose rate of 2.4 mg/min for 3 min and 20 sec., and 
finally the infusion line was flushed with saline, and 7) a 0.2 mg bolus of nitroglycerin was 
given. Average peak flow velocity (APV) was continuously recorded (FloMap, Cardiometrics 
(Volcano), Rancho Cordova, CA). At the end of each infusion step, an angiogram was done in 
the same position and angle. A coronary artery segment of 10 mm, 2-3 mm distal to the 
doppler wire, was used for mean diameter measurement by digitalized quantitative coronary 
angiography (QCA) (Quantcor QCA V5.0, Pie Medical Imaging, Maastricht, Netherlands) 
with the contrast-filled catheter as reference for calibration. Coronary blood flow (CBF) was 
calculated by use of APV and vessel diameter (CBF = πr2(½APV))16. FMD was calculated 
comparing mean diameter in a 10 mm segment (or at least 5 mm in shorter available segment 
lengths) of the study vessel proximal to the infusion catheter tip during saline infusion and 
during hyperemia induced by adenosine infusion. 
 
Measurements 
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Coronary vascular function was assessed by five indices: CBF at basal conditions during 
saline infusion (CBF-basal), infusion with acetylcholine (CBF-ach), adenosine (CBF-ado) and 
nitroglycerin (CBF-ntg), and proximal coronary FMD at maximum hyperemic flow (FMD-
hyperemia). Also, as a measure of endothelial function, response to acetylcholine infusion 
was calculated as percent increase in CBF-ach at each dose of acetylcholine compared to 
CBF-saline. A maximum increase in CBF-ach < 50% is considered representing endothelial 
dysfunction 9. 
At follow-up nine months and two years after inclusion, the same protocol and target 
segments were used. All invasive studies were performed by the same operator. A dedicated 
technician was in charge of all off-line measurements. 
 
Blood collection and analyses 
Blood samples were collected at baseline, after 9 and 24 months and stored at -80º C until 
processing. Folate and cobalamin were measured in serum samples, otherwise, sample 
handling and analyses were done as previously described 17. Glomerular filtration rate (GFR) 
was calculated according to the four-variable Modification of Diet in Renal Disease Equation 
18. 
 
Statistical analyses 
Continuous variables are reported as means (SD) if not otherwise indicated. Skewed variables 
are presented as median and selected percentiles. Categorical variables are presented as 
numbers and proportions. Chi-Square test was used for comparison of proportions. ANOVA 
was used to compare mean levels between groups, and paired-samples t-test was used for 
comparison within groups over time. Treatment effects of folic acid/B12 or vitamin B6 over 
time and interaction between treatment groups and acetylcholine dose during follow-up were 
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studied by repeated-measures ANOVA according to the 2 x 2 study design. Statistical 
package SPSS 13.0 (SPSS Inc., Chicago, IL) was used. Differences in time trends of flow 
(change during follow-up) by treatment were analyzed by a linear mixed-effect model with 
random intercept on subject level (S-PLUS 7.0 for Windows, Insightful Corporation, Seattle, 
WA). A two-tailed P < 0.05 was considered statistical significant. 
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RESULTS 
 
Subject and baseline characteristics 
A total of 40 patients (8 female and 32 male) with median age 57 (range 39-74) years were 
enrolled. Key baseline demographic and clinical characteristics and medical treatment are 
given in Table 1. Mean (SD) serum folate was 12.2 (6.5) nmol/L, cobalamin 381 (129) 
pmol/L, plasma pyridoxal phosphate (PLP) 43.3 (25.0) nmol/L and tHcy 10.7 (2.9) µmol/L. 
No significant differences between folic acid/B12 vs non-folic acid/B12 groups or between 
vitamin B6 vs non-B6 groups were found with respect to these characteristics. 
 
B-Vitamins and total homocysteine after treatment 
In patients randomized to folic acid and vitamin B12 treatment (groups A + B), serum folate 
concentrations increased significantly to 70.6 (18.6) nmol/L at 9 months (p<0.001) and serum 
cobalamin increased to 622 (215) pmol/L (p<0.001). There was a concurrent 34% reduction 
in plasma tHcy to 7.3 (2.0) µmol/L (p<0.001). At 24 months, tHcy remained at the same low 
level (7.4 (2.0) µmol/L, p=0.5). In the patients randomized to vitamin B6 alone or placebo 
(non-folic acid, groups C + D), no significant change in folate, vitamin B12 and tHcy were 
observed (all p-values >0.4). 
In patients treated with vitamin B6 (groups A + C), plasma PLP increased significantly 
to 375 (154) nmol/L (p<0.001) at 9 months. No significant change in PLP was observed in 
patients randomized to treatment with folic acid/vitamin B12 alone or placebo (groups B + D, 
p=0.8). Vitamin B6 treatment did not change levels of tHcy, folate or cobalamin (all p-values 
>0.6). 
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Basal coronary blood flow before and after B-vitamin treatment 
Basal coronary blood flow during saline infusion (CBF-basal) at inclusion was non-
significantly higher (mean (SD) 31.8 (11.8) mL/min) in patients allocated to folic acid /B12 
compared with patients not randomized to folic acid /B12 (25.7 (7.4) mL/min, p=0.06) 
(Figure 1). During the two years of follow-up, CBF-basal increased among patients treated 
with folic acid /B12, as apposed to a decrease in patients not receiving folic acid /B12, with a 
significant difference in time-trends of CBF-basal between the treatment groups (p=0.016) 
(Figure 1). After two years, CBF-basal was 36.3 (15.0) mL/min and 21.6 (9.2) mL/min in 
patients treated and not treated with folic acid/B12, respectively (p=0.002). Vitamin B6 
treatment was not associated with significant changes in CBF-basal after follow-up. 
 
Coronary blood flow and response to acetylcholine infusion 
Maximum achieved coronary blood flow during incremental dosages of acetylcholine (CBF-
ach) at inclusion was 59.5 (39.2) mL/min. At the same time, maximum flow response to 
acetylcholine, measured as percent change in CBF-ach compared to CBF-basal, was median 
(25 – 75th percentile) 90 (35-162) %. A total of 13 patients (33%) achieved increase in CBF-
ach less than 50%. Flow profile during infusion with incremental dosages of acetylcholine did 
not change after 9 months and two years of treatment with either folic acid/B12 (p=0.9) 
(Figure 2) or vitamin B6 (p=0.7). Likewise, flow response during acetylcholine infusion, as a 
measure of endothelial-dependent response, did not change significantly after B-vitamin 
intervention for two years (Table 2, all p-values ≥ 0.45). 
 
Maximum hyperemia and flow-dependent response following adenosine infusion 
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Adenosine infusion was used to achieve maximum hyperemic coronary flow (CBF-ado), 
mainly due to effects on microcirculation15. At study start, there was no difference in CBF-
ado between the folic acid/B12 group, mean (SD) 96.8 (39.1) mL/min, and the non-folic 
acid/B12 group, 90.0 (32.9) mL/min (p=0.6) (Figure 1). Similar to observations with CBF-
basal, treatment with folic acid /B12 was associated with a gradual increase in CBF-ado, 
whereas a decrease in CBF-ado was seen among patients not receiving folic acid /B12. As a 
result, there was a significant difference in time-trends of CBF-ado according to folic 
acid/B12 therapy (p=0.049) (Figure 1). At two years, mean (SD) CBF-ado was 121.8 (77.5) 
mL/min in patients allocated to folic acid/B12 compared to 76.0 (33.1) mL/min in patients not 
receiving folic acid /B12 (p=0.04). Vitamin B6 had no effect on CBF-ado (p ≥ 0.3). 
FMD-hyperemia, a measurement of endothelial function, was 0.10 (0.23) mm at 
baseline, with no overall change at 9 months (0.10 (0.21) mm, p=0.9) or 2 years (0.13 (0.39) 
mm, p=0.6). There was no significant difference in FMD-hyperemia according to folic 
acid/B12 or vitamin B6 during follow-up (repeated measure ANOVA; p=0.16 and p=0.84 
respectively). 
 
Endothelial-independent flow response following nitroglycerin infusion 
Coronary blood flow after nitoglycerin administration (CBF-ntg) was 109.1 (34.3) mL/min in 
the folic acid/B12 group and 94.1 (34.5) mL/min in non-folic acid group at randomization 
(p=0.18). Although we observed a significant difference in CBF-ntg at two years between 
patients treated with folic acid/B12 compared to those not treated with folic acid/B12 (133.5 
(62.8) and 88.9 (45.0) mL/min respectively (p = 0.02), the difference in time-trends of CBF-
ntg did not reach statistically significance (p=0.10) (Figure 1). CBF-ntg was not influenced by 
vitamin B6 treatment (p≥0.5). 
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DISCUSSION 
In this randomized controlled trial, we have shown that two years of treatment with folic 
acid/vitamin B12 improved basal coronary blood flow and blood flow at maximum 
hyperaemia induced by adenosine. In contrast, folic acid/vitamin B12 did not improve 
coronary endothelial function as measured by flow-induced change in coronary vessel 
diameter or change in flow following stimulation with acetylcholine. Vitamin B6 treatment 
did not change any of the vascular function variables. 
 
Measurements in different target organs 
We have investigated parameters of vascular function in coronary vessels. This is in contrast 
to most other studies on endothelial function and B-vitamins, which have measured brachial 
FMD 10. The relation between coronary endothelial function and brachial FMD is uncertain, 
and, although one study found a significant but weak relation between brachial FMD and 
coronary response to acetylcholine 19, other studies find no such relation 20,21. Therefore, 
caution must be taken when comparing results obtained in different target organs. 
 
Strengths and weaknesses 
Intra-coronary measurements in a population with no folate fortification, combined with long-
term follow-up, are major strengths of our study. The factorial design allowed us to examine 
separate effects of folic acid/B12 and vitamin B6 treatment. Although the number of patients 
may seem limited, this is the largest study on folate therapy and coronary vascular function. 
 
Earlier studies on coronary vascular function 
There is only one published study on the effect of B-vitamins on coronary flow in patients 
with CAD 13. A total of 15 patients were randomized to treatment with folic acid (5 mg/d) and 
 12
Coronary vascular function and folic acid therapy 
vitamin B12 (0.4 mg/d) or placebo for six months. B-vitamin treatment was associated with a 
significant improvement in acetylcholine-induced coronary blood flow. It is noteworthy that 
these patients had relatively high baseline tHcy (17.9 µmol/L), few patients received statin 
therapy, and a high dose of folic acid was used. In contrast, we found an effect of folic 
acid/vitamin B12 on basal and maximal hyperemic coronary blood flow, but no effect on 
acetylcholine stimulated flow. 
 
Possible mechanisms 
The reported relations between folate or tHcy levels and brachial endothelial-dependent FMD 
are somewhat conflicting 22. However, most studies suggest that a rapid increase in plasma 
tHcy levels, as observed during methionine or homocysteine loading 6,10,22, or after a protein 
rich meal 7, impairs brachial endothelial function, while high doses of folic acid improve 
endothelial function, possibly partly independent of its homocysteine-lowering effect10,23. The 
mechanism by which homocysteine impairs endothelial function may involve homocysteine-
induced reduction of intracellular tetrahydrobiopterin, thereby causing eNOS-uncoupling 24. 
Folic acid, through its circulating form, 5-methyltetrahydrofolate, is believed to enhance 
regeneration of tetrahydrobiopterin and improve eNOS-coupling and thereby improve 
endothelial function independently of homocysteine 25,26. Recent data from an isolated rat 
heart model supports our findings of increased coronary flow by folic acid treatment, and 
suggests a mechanistic role of NO 27. 
Whereas NO is an established regulator of vascular tone, there is some evidence that 
endothelium-derived hyperpolarizing factor (EDHF) plays a major role in regulating 
microcirculation 28. In renal microcirculation of rats, EDHF-mediated vasodilatation is 
impaired during methionine loading and partly restored by 5-methyltetrahydrofolate 29. This 
suggests an additional mechanism by which folic acid therapy in our patients has improved 
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vascular tone and microcirculation, since resting coronary flow (CBF-basal) and maximal 
hyperemia (CBF-ado) largely depend on microvascular dilatation in non obstructive coronary 
vessels 15. A beneficial effect on microvascular flow, together with reduced arterial stiffness 
30, may explain a reduced frequency of electrocardiographic changes at exercise tests 31 and 
reduction in blood pressure 32 observed after treatment with folic acid. 
 
Dosage of folic acid 
High doses of folic acid 5 – 10 mg/d improve endothelial function as measured by FMD 33. 
Likewise, a short-term study (six weeks) in patients with CAD showed no effect on forearm 
FMD with 0.4 mg/d of folic acid, but a significant improvement with 5 mg daily 11. In 
contrast, a study using magnetic resonance imaging revealed that both 0.4 mg/d and 5 mg/d of 
folic acid for seven weeks improved FMD in brachial artery 30. The latter study also 
demonstrated that the low-dose folic acid significantly enhances folate status in the vascular 
endothelium, with no significant additional increase in vascular tissue 5-
methyltetrahydrofolate level in the high-dose group 30. Thus, our dose of 0.8 mg/d should be 
adequate to obtain optimal effect on endothelial-dependent response and vascular stiffness. 
 
Clinical trials 
If long-term treatment with folic acid improves vascular function, this may have important 
clinical implications. and explain a reduction in stroke mortality rate observed in North 
America following folic acid fortification 34 and a reduction in stroke events in the HOPE-2 
study 35. Prior studies have demonstrated that even minor reductions in blood pressure are 
associated with significant lower risk of stroke, but with less effect on ischemic heart disease 
36. Thus, potential treatment effects of folic acid related to a reduction in blood pressure, may 
act differently upon risk of stroke and CAD 1,36. Notably, folic acid/B12 therapy has not been 
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associated with reduced risk of coronary events in any of the published randomized trials with 
B-vitamin intervention 37,38. 
 
Vitamin B6 
Data on vitamin B6 and vascular function are sparse 39,40, and our study is the first to examine 
the effect of B6 in the coronary circulation. We observed no effect of vitamin B6 treatment on 
the vascular indices despite marked increases in plasma concentrations of PLP. Vitamin B6 
status is associated with CVD in some observational studies 41,42, but supplementation studies 
with vitamin B6 have revealed no clinical benefits 37. 
 
Conclusion 
In patients with stable CAD, we demonstrate that treatment with moderate doses of folic acid 
in addition to vitamin B12 is associated with a significant increase in both basal and in 
adenosine-stimulated maximal coronary blood flow, reflecting improved vascular function. 
This treatment does however not change endothelial-dependent acetylcholine-induced 
response or flow-mediated coronary dilatation. Treatment with high doses of vitamin B6 
shows no effect on coronary vascular function. The effect of folate therapy on vascular 
function should be furthered studied. 
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